[[id:27728, fullName:BRAF S602F, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF S602F lies within the protein kinase domain of the Braf protein (UniProt.org). S602F has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:602], [id:27734, fullName:BRAF V639I, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF V639I lies within the protein kinase domain of the Braf protein (UniProt.org). V639I has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:639], [id:23672, fullName:BRAF amp, impact:none, proteinEffect:no effect, geneVariantDescriptions:[[description:BRAF amplification indicates an increased number of copies of the Braf gene. However, the mechanism causing the increase is unspecified., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:null], [id:27711, fullName:BRAF L711F, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF L711F lies within the protein kinase domain of the Braf protein (UniProt.org). L711F has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:711], [id:3127, fullName:BRAF A598V, impact:missense, proteinEffect:gain of function - predicted, geneVariantDescriptions:[[description:BRAF A598V lies within the protein kinase domain of the Braf protein (UniProt.org). A598V is associated with increased activation of Braf and downstream Mek and Erk in human tumor samples (PMID: 19200582), and is therefore predicted to confer a gain of function to the Braf protein., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:1894, pubMedId:19200582, title:Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma., url:http://www.ncbi.nlm.nih.gov/pubmed/19200582]]]], position:598], [id:28207, fullName:BRAF N581K, impact:missense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF N581K lies within the protein kinase domain of the Braf protein (UniProt.org). N581K has not been biochemically characterized, but demonstrates decreased transformation ability in cell culture (PMID: 29533785), and is therefore predicted to confer a loss of function to the Braf protein., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:581], [id:28189, fullName:BRAF G258V, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF G258V lies within the protein kinase domain of the Braf protein (UniProt.org). G258V has not been biochemically characterized, but results in increased transformation ability compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:258], [id:28192, fullName:BRAF G606W, impact:missense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF G606W lies within the protein kinase domain of the Braf protein (UniProt.org). G606W has not been biochemically characterized, but demonstrates decreased transformation ability in cell culture (PMID: 29533785), and is therefore predicted to confer a loss of function to the Braf protein., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:606], [id:23128, fullName:BRAF N581Y, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF N581Y lies within the protein kinase domain of the Braf protein (UniProt.org). N581Y has been identified in the scientific literature (PMID: 19474002, PMID: 26084293), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, May 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:10345, pubMedId:26084293, title:ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma., url:http://www.ncbi.nlm.nih.gov/pubmed/26084293], [id:7500, pubMedId:19474002, title:Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/19474002]]]], position:581], [id:28210, fullName:BRAF Q609E, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF Q609E lies within the protein kinase domain of the Braf protein (UniProt.org). Q609E results in increased transformation ability compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:609], [id:27720, fullName:BRAF R188T, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF R188T lies within the protein kinase domain of the Braf protein (UniProt.org). R188T has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:188], [id:1226, fullName:BRAF inact mut, impact:unknown, proteinEffect:loss of function, geneVariantDescriptions:[[description:BRAF inact mut indicates that this variant results in a loss of function of the Braf protein. However, the specific amino acid change has not been identified., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:null], [id:28204, fullName:BRAF M517I, impact:missense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF M517I lies within the protein kinase domain of the Braf protein (UniProt.org). M517I has not been biochemically characterized, but demonstrates decreased transformation ability in cell culture (PMID: 29533785), and is therefore predicted to confer a loss of function to the Braf protein., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:517], [id:28590, fullName:BRAF H574Q, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF H574Q lies within the protein kinase domain of the Braf protein (UniProt.org). H574Q confers a gain of function to the Braf protein as indicated by increased Erk phosphorylation in culture and tumor formation in animal models, and confers resistance to Egfr inhibitors in culture (PMID: 27478040)., references:[[id:8124, pubMedId:27478040, title:High-throughput Phenotyping of Lung Cancer Somatic Mutations., url:http://www.ncbi.nlm.nih.gov/pubmed/27478040], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:574], [id:23125, fullName:BRAF K499E, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF K499E lies within the protein kinase domain of the Braf protein (UniProt.org). K499E confers a gain of function to the Braf protein as demonstrated by increased Braf kinase activity and downstream signaling, activation of ELK-dependent signaling in reporter assays, and foci formation in cultured cells (PMID: 16474404, PMID: 18413255, PMID: 26065894)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:12145, pubMedId:18413255, title:Biochemical characterization of novel germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome., url:http://www.ncbi.nlm.nih.gov/pubmed/18413255], [id:5844, pubMedId:16474404, title:Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome., url:http://www.ncbi.nlm.nih.gov/pubmed/16474404], [id:5843, pubMedId:26065894, title:Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation., url:http://www.ncbi.nlm.nih.gov/pubmed/26065894]]]], position:499], [id:3184, fullName:BRAF W450*, impact:nonsense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF W450* results in a premature truncation the Braf protein at amino acid 450 of 766 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), R450* is predicted to lead to a loss of Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:450], [id:19431, fullName:BRAF T488_P492del, impact:deletion, proteinEffect:gain of function - predicted, geneVariantDescriptions:[[description:BRAF T488_P492del results in the deletion of five amino acids near the alphaC-helix region of the protein kinase domain in the Braf protein from amino acids 488 to 492 (PMID: 26732095). T488_P492del results in activation of Mek in cell culture (PMID: 26996308), and similar Braf deletions are activating (PMID: 26996308, PMID: 26732095), and therefore T488_P492del is predicted to confer a gain of function to the Braf function., references:[[id:4801, pubMedId:26732095, title:Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120., url:http://www.ncbi.nlm.nih.gov/pubmed/26732095], [id:12174, pubMedId:26996308, title:Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2., url:http://www.ncbi.nlm.nih.gov/pubmed/26996308]]]], position:488], [id:27714, fullName:BRAF P162S, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF P162S lies within the protein kinase domain of the Braf protein (UniProt.org). P162S has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:162], [id:29179, fullName:BRAF S363F, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF S363F does not lie within any known functional domains of the Braf protein (UniProt.org). S363F has been identified in the scientific literature (PMID: 29903896), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jan 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:13465, pubMedId:29903896, title:Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas., url:http://www.ncbi.nlm.nih.gov/pubmed/29903896]]]], position:363], [id:27722, fullName:BRAF R389C, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF R389C lies within the protein kinase domain of the Braf protein (UniProt.org). R389C has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:389], [id:28200, fullName:BRAF L245F, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF L245F lies within the Phorbol-ester/DAG-type zinc finger domain of the Braf protein (UniProt.org). L245F results in increased transformation ability compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:245], [id:29457, fullName:BRAF T599X, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF T599X indicates any Braf missense mutation that results in replacement of the threonine (T) at amino acid 599 by a different amino acid., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:599], [id:3520, fullName:BRAF R462I, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF R462I lies within the protein kinase domain of the Braf protein (UniProt.org). R462I results in activation of Braf and increased Erk signaling in cell culture (PMID: 15035987) but, in two different cell lines, induced similar cell proliferation and cell viability as wild-type Braf (PMID: 29533785), and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:146, pubMedId:15035987, title:Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., url:http://www.ncbi.nlm.nih.gov/pubmed/15035987], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed]]]], position:462], [id:895, fullName:BRAF D594N, impact:missense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF D594N lies within the protein kinase domain of the Braf protein (UniProt.org). D594N results in impaired Braf kinase activity, but leads to activation of Erk signaling through CRAF in cell culture (PMID: 28783719), and demonstrates decreased transforming ability compared to wild-type Braf in one of two cell lines in culture (PMID: 29533785), and therefore is predicted to confer a loss of function to the Braf protein., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:9692, pubMedId:28783719, title:Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., url:http://www.ncbi.nlm.nih.gov/pubmed/28783719], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:594], [id:3136, fullName:BRAF F595S, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF F595S lies within the protein kinase domain of the Braf protein (UniProt.org). F595S has been identified in sequencing studies (PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:7101, pubMedId:15331929, title:B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome., url:http://www.ncbi.nlm.nih.gov/pubmed/15331929]]]], position:595], [id:29443, fullName:BRAF R462X, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF R462X indicates any Braf missense mutation that results in replacement of the arginine (R) at amino acid 462 by a different amino acid., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:462], [id:23138, fullName:BRAF T599dup, impact:duplication, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF T599dup (also referred to T599_V600insT) indicates the insertion of the duplicate amino acid, tyrosine (T)-599, in the protein kinase domain of the Braf protein (UniProt.org). T599dup confers a gain of function to the Braf protein as demonstrated by increased kinase activity and phosphorylation of downstream Mek and Erk, and is transforming in cell culture (PMID: 21190184)., references:[[id:1910, pubMedId:21190184, title:Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma., url:http://www.ncbi.nlm.nih.gov/pubmed/21190184], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:599], [id:3138, fullName:BRAF G469S, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF G469S is a hotspot mutation within the protein kinase domain of the Braf protein (UniProt.org). G469S results in increased Erk phosphorylation (PMID: 27478040) and induces increased cell proliferation and cell viability compared to wild-type Braf in culture (PMID: 29533785)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:8124, pubMedId:27478040, title:High-throughput Phenotyping of Lung Cancer Somatic Mutations., url:http://www.ncbi.nlm.nih.gov/pubmed/27478040], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:469], [id:13358, fullName:BRAF V504_R506dup, impact:duplication, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF V504_R506dup (also referred to as R506_K507insVLR) lies within the protein kinase domain (UniProt.org). V504_R506dup confers a gain of function to the Braf protein as demonstrated by stabilization of Braf homodimers and increased downstream Erk phosphorylation in cultured cells (PMID: 23817572, PMID: 30575814), and is associated with increased Erk1/2 phosphorylation in human tumor samples (PMID: 29544532)., references:[[id:1902, pubMedId:23817572, title:Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma., url:http://www.ncbi.nlm.nih.gov/pubmed/23817572], [id:15556, pubMedId:30575814, title:Recurrent somatic BRAF insertion (p.V504_R506dup): a tumor marker and a potential therapeutic target in pilocytic astrocytoma., url:http://www.ncbi.nlm.nih.gov/pubmed/30575814], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:12166, pubMedId:29544532, title:BRAF activating mutations involving the β3-αC loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma., url:http://www.ncbi.nlm.nih.gov/pubmed/29544532]]]], position:504], [id:23122, fullName:BRAF G469del, impact:deletion, proteinEffect:loss of function, geneVariantDescriptions:[[description:BRAF G469del results in the deletion of an amino acid in the protein kinase domain of the Braf protein at amino acid 469 (UniProt.org). G469del demonstrates decreased Braf kinase activity, does not activate downstream ERK, and is minimally transforming in cell culture (PMID: 23833300)., references:[[id:5855, pubMedId:23833300, title:Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/23833300], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:469], [id:27723, fullName:BRAF R509G, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF R509G lies within the protein kinase domain of the Braf protein (UniProt.org). R509C has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:509], [id:894, fullName:BRAF Y472C, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF Y472C lies within the protein kinase domain of the Braf protein (UniProt.org). Y472C results in impaired Braf kinase activity, but paradoxically increases Mek and Erk signaling through C-raf transactivation (PMID: 22649091), however, in two different cell lines, Y472C induces similar cell proliferation and cell viability as compared to wild-type Braf (PMID: 29533785), and therefore, its effect on Braf protein function is unknown., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:423, pubMedId:22649091, title:Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib., url:http://www.ncbi.nlm.nih.gov/pubmed/22649091]]]], position:472], [id:3137, fullName:BRAF G464R, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF G464R (also reported as G463R) lies within the protein kinase domain of the Braf protein (UniProt.org). G464R results in increased Braf kinase activity, increased downstream Erk signaling (PMID: 15046639), and induces cell proliferation and cell viability in culture (PMID: 29533785)., references:[[id:1166, pubMedId:15046639, title:Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis., url:http://www.ncbi.nlm.nih.gov/pubmed/15046639], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:464], [id:4984, fullName:BRAF D594A, impact:missense, proteinEffect:loss of function, geneVariantDescriptions:[[description:BRAF D594A lies within the protein kinase domain of the Braf protein (UniProt.org). D594A results in a lack of Braf kinase activity (PMID: 20141835, PMID: 20978199, PMID: 28783719), promotes aneupolidy (PMID: 20978199), and in one of two cell lines demonstrated decreased transformation ability compared to wild-type Braf in culture (PMID: 29533785), but leads to activation of Mek and Erk through cooperation with activated RAS and transactivation of CRAF in cell culture and mouse models (PMID: 20141835, PMID: 20978199, PMID: 28783719)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:424, pubMedId:20141835, title:Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF., url:http://www.ncbi.nlm.nih.gov/pubmed/20141835], [id:2517, pubMedId:20978199, title:BRAF inactivation drives aneuploidy by deregulating CRAF., url:http://www.ncbi.nlm.nih.gov/pubmed/20978199], [id:9692, pubMedId:28783719, title:Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., url:http://www.ncbi.nlm.nih.gov/pubmed/28783719]]]], position:594], [id:29618, fullName:BRAF A81_M438del, impact:deletion, proteinEffect:gain of function - predicted, geneVariantDescriptions:[[description:BRAF A81_M438del results in the deletion of 358 amino acids of the Braf protein from amino acids 81 to 438 (UniProt.org). A81_M438del (reported as internal deletion of exons 3-10) has not been characterized, however, due to the deletion of the CR1 autoinhibitory domain and preservation of the protein kinase domain (PMID: 23890088, PMID: 22113612, PMID: 29171936), A81_M438del is predicted to lead to a gain of Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:14626, pubMedId:22113612, title:RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)., url:http://www.ncbi.nlm.nih.gov/pubmed/22113612], [id:14627, pubMedId:29171936, title:BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy., url:http://www.ncbi.nlm.nih.gov/pubmed/29171936], [id:3413, pubMedId:23890088, title:Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy., url:http://www.ncbi.nlm.nih.gov/pubmed/23890088]]]], position:81], [id:902, fullName:BRAF L597S, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF L597S lies within the protein kinase domain of the Braf protein (UniProt.org). L597S results in activation of Braf as indicated by increased phosphorylation of Mek and Erk in cell culture (PMID: 22798288) and induces cell proliferation and cell viability in culture (PMID: 29533785)., references:[[id:3, pubMedId:22798288, title:BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors., url:http://www.ncbi.nlm.nih.gov/pubmed/22798288], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:597], [id:27721, fullName:BRAF R271H, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF R271H lies within the protein kinase domain of the Braf protein (UniProt.org). R271H has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:271], [id:3182, fullName:BRAF V600L, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF V600L (previously reported as V599L) lies within the activation segment of the protein kinase domain of the Braf protein (PMID: 15035987). V600L results in increased cell proliferation and cell viability compared to wild-type Braf in one of two cell lines in culture (PMID: 29533785), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:146, pubMedId:15035987, title:Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., url:http://www.ncbi.nlm.nih.gov/pubmed/15035987]]]], position:600], [id:23120, fullName:BRAF F468C, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF F468C (also referred to as F467C) lies within the protein kinase domain of the Braf protein (UniProt.org). F468C confers a gain of function to the Braf protein as demonstrated by increased Braf kinase activity and downstream Erk phosphorylation, activation of NFkappaB signaling in reporter assays, and transformation of cultured cells (PMID: 15150094)., references:[[id:147, pubMedId:15150094, title:Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation., url:http://www.ncbi.nlm.nih.gov/pubmed/15150094], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:468], [id:27717, fullName:BRAF P407L, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF P407L lies within the protein kinase domain of the Braf protein (UniProt.org). P407L has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:407], [id:19430, fullName:BRAF P490_Q494del, impact:deletion, proteinEffect:gain of function - predicted, geneVariantDescriptions:[[description:BRAF P490_Q494del results in the deletion of five amino acids near the alphaC-helix region of the protein kinase domain in the Braf protein from amino acids 490 to 494 (PMID: 26732095). P490_Q494del results in activation of Mek in cell culture (PMID: 26996308), and similar Braf deletions are activating (PMID: 26996308, PMID: 26732095), and therefore P490_Q494del is predicted to confer a gain of function to the Braf function., references:[[id:12174, pubMedId:26996308, title:Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2., url:http://www.ncbi.nlm.nih.gov/pubmed/26996308], [id:4801, pubMedId:26732095, title:Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120., url:http://www.ncbi.nlm.nih.gov/pubmed/26732095]]]], position:490], [id:25796, fullName:BRAF A598S, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF A598S lies within the protein kinase domain of the Braf protein (UniProt.org). A598S has not been characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:598], [id:29626, fullName:BRAF V47_G393del, impact:deletion, proteinEffect:gain of function - predicted, geneVariantDescriptions:[[description:BRAF V47_G393del results in the deletion of 347 amino acids of the Braf protein from amino acids 47 to 393 (UniProt.org). V47_G393del (reported as internal deletion of exons 2-9) has not been characterized, however, due to the deletion of the CR1 autoinhibitory domain and preservation of the protein kinase domain (PMID: 23890088, PMID: 22113612, PMID: 29171936), V47_G393del is predicted to lead to a gain of Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:14626, pubMedId:22113612, title:RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)., url:http://www.ncbi.nlm.nih.gov/pubmed/22113612], [id:14627, pubMedId:29171936, title:BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy., url:http://www.ncbi.nlm.nih.gov/pubmed/29171936], [id:3413, pubMedId:23890088, title:Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy., url:http://www.ncbi.nlm.nih.gov/pubmed/23890088]]]], position:47], [id:19426, fullName:BRAF N486_P490del, impact:deletion, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF N486_P490del results in the deletion of five amino acids near the alphaC-helix region of the kinase domain (PMID: 26732095). N486_P490del confers a gain of function to the Braf protein as indicated by activation of the MAPK signaling pathway and increased cell proliferation in culture (PMID: 26732095)., references:[[id:4801, pubMedId:26732095, title:Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120., url:http://www.ncbi.nlm.nih.gov/pubmed/26732095]]]], position:486], [id:4983, fullName:BRAF D587G, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF D587G lies within the protein kinase domain of the Braf protein (UniProt.org). D587G has been identified in the scientific literature (PMID: 24803665), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:12613, pubMedId:24803665, title:Structure-energy-based predictions and network modelling of RASopathy and cancer missense mutations., url:http://www.ncbi.nlm.nih.gov/pubmed/24803665]]]], position:587], [id:2635, fullName:BRAF K601Q, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF K601Q lies within the activation loop in the kinase domain of the Braf protein (PMID: 19206169). K601Q confers a gain of function on Braf, as indicated by increased MEK and ERK phosphorylation, and is transforming in cell culture (PMID: 19206169, PMID: 29533785). , references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:760, pubMedId:19206169, title:Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum., url:http://www.ncbi.nlm.nih.gov/pubmed/19206169]]]], position:601], [id:29458, fullName:BRAF K601X, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF K601X indicates any Braf missense mutation that results in replacement of the lysine (K) at amino acid 601 by a different amino acid., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:601], [id:29449, fullName:BRAF L485X, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF L485X indicates any Braf missense mutation that results in replacement of the leucine (L) at amino acid 485 by a different amino acid., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:485], [id:897, fullName:BRAF D594G, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF D594G lies within the protein kinase domain of the Braf protein (UniProt.org). D594G has been demonstrated to result in impaired Braf kinase activity, but leads to increased activation of Erk signaling through CRAF in cell culture (PMID: 18794803, PMID: 28783719), however, has increased transforming ability in one of two cell lines in culture (PMID: 29533785), and therefore its effect on Braf protein function is unknown., references:[[id:7, pubMedId:18794803, title:CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations., url:http://www.ncbi.nlm.nih.gov/pubmed/18794803], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:9692, pubMedId:28783719, title:Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., url:http://www.ncbi.nlm.nih.gov/pubmed/28783719]]]], position:594], [id:1789, fullName:BRAF W531C, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF W531C lies within the protein kinase domain of the Braf protein (UniProt.org). W531C results in the weak activation of MEK signaling and does not induce transformation in cell culture (PMID: 19206169), but in two different cell lines, W531C demonstrates increased cell proliferation and viability as compared to wild-type Braf (PMID: 29533785), and therefore, its effect on Braf protein function is unknown., references:[[id:760, pubMedId:19206169, title:Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum., url:http://www.ncbi.nlm.nih.gov/pubmed/19206169], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:531], [id:28197, fullName:BRAF H725Y, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF H725Y does not lie with any known functional domains of the Braf protein (UniProt.org). H725Y has not been biochemically characterized, but results in increased transformation ability compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed]]]], position:725], [id:23131, fullName:BRAF L485_P490del, impact:deletion, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF L485_P490del results in the deletion of six amino acids within the beta-3/alpha-C helix loop in the protein kinase domain of the Braf protein (PMID: 26732095, UniProt.org). L485_P490del confers a gain of function to the Braf protein as demonstrated by increased kinase activity, phosphorylation of downstream Mek and Erk, and transformation ability in cell culture (PMID: 26732095, PMID: 26996308), and is associated with resistance to vemurafenib in cell culture (PMID: 26996308)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:4801, pubMedId:26732095, title:Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120., url:http://www.ncbi.nlm.nih.gov/pubmed/26732095], [id:12174, pubMedId:26996308, title:Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2., url:http://www.ncbi.nlm.nih.gov/pubmed/26996308]]]], position:485], [id:3143, fullName:BRAF I592M, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF I592M lies within the protein kinase domain of the Braf protein (UniProt.org). I592M has been identified in sequencing studies (PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar  2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:7101, pubMedId:15331929, title:B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome., url:http://www.ncbi.nlm.nih.gov/pubmed/15331929]]]], position:592], [id:27725, fullName:BRAF R719S, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF R719S lies within the protein kinase domain of the Braf protein (UniProt.org). R719S has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:719], [id:25027, fullName:BRAF N20T, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF N20T does not lie within any known functional domains of the Braf protein (UniProt.org). N20T has not been characterized in the scientific literature and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed]]]], position:20], [id:27700, fullName:BRAF A762V, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF A762V lies within the protein kinase domain of the Braf protein (UniProt.org). A762V has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:762], [id:28898, fullName:BRAF L514V, impact:missense, proteinEffect:gain of function - predicted, geneVariantDescriptions:[[description:BRAF L514V lies within the protein kinase domain of the Braf protein (UniProt.org). L514V is predicted to lead to a gain of Braf function as indicated by moderate increase of Mek and Erk phosphorylation in culture, enhanced dimerization when expressed in cis with BRAF V600E, and is associated with resistance to Raf inhibitors (PMID: 29880583)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:12771, pubMedId:29880583, title:A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor., url:http://www.ncbi.nlm.nih.gov/pubmed/29880583]]]], position:514], [id:19427, fullName:BRAF V487_P492delinsA, impact:indel, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF V487_P492delinsA results in a deletion of six amino acids near the alphaC-helix region of the kinase domain of the Braf protein combined with the insertion of one new amino acid in the same location (PMID: 26732095). V487_P492delinsA confers a gain of function to the Braf protein as indicated by increased pathway signaling and cell proliferation in culture (PMID: 26732095)., references:[[id:4801, pubMedId:26732095, title:Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120., url:http://www.ncbi.nlm.nih.gov/pubmed/26732095]]]], position:487], [id:25026, fullName:BRAF A712T, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF A712T lies within the protein kinase domain of the Braf protein (UniProt.org). A712T has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:712], [id:23099, fullName:BRAF A728V, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF A728V (also referred to as A727V) does not lie within any known functional domains of the Braf protein (UniProt.org). A728V results in an intermediate increase in Braf kinase activity compared to wild-type Braf and increased Erk phosphorylation in cell culture (PMID: 15035987)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:146, pubMedId:15035987, title:Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., url:http://www.ncbi.nlm.nih.gov/pubmed/15035987]]]], position:728], [id:4990, fullName:BRAF N581I, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF N581I lies within the protein kinase domain of the Braf protein (UniProt.org). N581I results in low Braf kinase activity and Ras-dependent activation of Erk signaling in cell culture (PMID: 28783719), however, also results in increased transformation ability compared to wild-type Braf in culture (PMID: 29533785), and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:9692, pubMedId:28783719, title:Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., url:http://www.ncbi.nlm.nih.gov/pubmed/28783719], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:581], [id:29178, fullName:BRAF R239Q, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF R239Q lies within the phorbol-ester/DAG-type zinc finger domain of the Braf protein (UniProt.org). R239Q has been identified in the scientific literature (PMID: 29903896), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jan 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:13465, pubMedId:29903896, title:Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas., url:http://www.ncbi.nlm.nih.gov/pubmed/29903896]]]], position:239], [id:23135, fullName:BRAF T529I, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF T529I is a gatekeeper mutation that lies within the protein kinase domain of the Braf protein (PMID: 20538618). T529I has been demonstrated to confer resistance to Raf inhibitors in the context of BRAF V600E (PMID: 20538618), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Apr 2019)., references:[[id:5859, pubMedId:20538618, title:Gatekeeper mutations mediate resistance to BRAF-targeted therapies., url:http://www.ncbi.nlm.nih.gov/pubmed/20538618], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed]]]], position:529], [id:27713, fullName:BRAF P141L, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF P141L lies within the protein kinase domain of the Braf protein (UniProt.org). P141L has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:141], [id:28202, fullName:BRAF L618F, impact:missense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF L618F lies within the protein kinase domain of the Braf protein (UniProt.org). L618F has not been biochemically characterized, but demonstrates decreased transformation ability in cell culture (PMID: 29533785), and is therefore predicted to confer a loss of function to the Braf protein., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:618], [id:29608, fullName:BRAF V47_D380del, impact:deletion, proteinEffect:gain of function - predicted, geneVariantDescriptions:[[description:BRAF V47_D380del results in the deletion of 334 amino acids of the Braf protein from amino acids 47 to 380 (UniProt.org). V47_D380del (reported as internal deletion of exons 2-8) has been associated with resistance to Mek inhibitors in a patient (PMID: 29171936), and is predicted to lead to a gain of Braf protein function due to the deletion of the CR1 autoinhibitory domain and preservation of the protein kinase domain (PMID: 23890088, PMID: 22113612)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:14626, pubMedId:22113612, title:RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)., url:http://www.ncbi.nlm.nih.gov/pubmed/22113612], [id:14627, pubMedId:29171936, title:BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy., url:http://www.ncbi.nlm.nih.gov/pubmed/29171936], [id:3413, pubMedId:23890088, title:Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy., url:http://www.ncbi.nlm.nih.gov/pubmed/23890088]]]], position:47], [id:896, fullName:BRAF D594H, impact:missense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF D594H lies within the protein kinase domain of the Braf protein (UniProt.org). D594H results in a loss of Braf kinase activity, but leads to Ras-dependent activation of Erk signaling through CRAF (PMID: 28783719), and demonstrates decreased transforming activity compared to wild-type Braf in one of two cell lines in culture (PMID: 29533785), and therefore is predicted to confer a loss of function to the Braf protein., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:9692, pubMedId:28783719, title:Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., url:http://www.ncbi.nlm.nih.gov/pubmed/28783719]]]], position:594], [id:26916, fullName:BRAF V459L, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF V459L lies within the protein kinase domain of the Braf protein (UniProt.org). V459L results in impaired Braf kinase activity and leads to Ras-dependent activation of Erk in culture (PMID: 28783719), however, in two different cell lines, induces similar cell proliferation and cell viability as compared to wild-type Braf (PMID: 29533785), and therefore, its effect on Braf protein function is unknown., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:9692, pubMedId:28783719, title:Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., url:http://www.ncbi.nlm.nih.gov/pubmed/28783719]]]], position:459], [id:27394, fullName:BRAF L485W, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF L485W lies within the protein kinase domain of the Braf protein (UniProt.org). L485W results in increased transformation ability compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:485], [id:3135, fullName:BRAF D587E, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF D587E lies within the protein kinase domain of the Braf protein (UniProt.org). D587E has been identified in sequencing studies (PMID: 27034166), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:9191, pubMedId:27034166, title:Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/27034166]]]], position:587], [id:29577, fullName:BRAF S465A, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF S465A lies within the protein kinase domain of the Braf protein (UniProt.org). S465A results in basal Mek phosphorylation and Mek phosphorylation upon Ras activation to similar levels of wild-type Braf in culture (PMID: 27034005), and therefore, is predicted to have no effect on Braf protein function., references:[[id:14533, pubMedId:27034005, title:Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles., url:http://www.ncbi.nlm.nih.gov/pubmed/27034005], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:465], [id:27707, fullName:BRAF G421V, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF G421V lies within the protein kinase domain of the Braf protein (UniProt.org). G421V has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:421], [id:23119, fullName:BRAF E501K, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF E501K lies within the protein kinase domain of the Braf protein (UniProt.org). E501K results in ELK transactivation similar to wild-type Braf in a reporter assay (PMID: 16474404), however, also demonstrates decreased Braf kinase activity in culture (PMID: 17603482), and therefore, its effect on Braf protein function is unknown., references:[[id:5844, pubMedId:16474404, title:Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome., url:http://www.ncbi.nlm.nih.gov/pubmed/16474404], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:494, pubMedId:17603482, title:Germline gain-of-function mutations in RAF1 cause Noonan syndrome., url:http://www.ncbi.nlm.nih.gov/pubmed/17603482]]]], position:501], [id:3481, fullName:BRAF fusion, impact:unknown, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF fusion indicates a fusion of the BRAF gene, but the fusion partner is unknown., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:null], [id:28213, fullName:BRAF T599A, impact:missense, proteinEffect:loss of function, geneVariantDescriptions:[[description:BRAF T599A lies within the protein kinase domain of the Braf protein (UniProt.org). T599A does not result in increased MEK or ERK phosphorylation and does not transactivate CRAF (PMID: 22506009), and demonstrates decreased transformation ability compared to wild-type Braf in cell culture (PMID: 29533785)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:12160, pubMedId:22506009, title:B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease., url:http://www.ncbi.nlm.nih.gov/pubmed/22506009], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:599], [id:3134, fullName:BRAF D587A, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF D587A lies within the protein kinase domain of the Braf protein (UniProt.org). D587A has been identified in sequencing studies (PMID: 14500346), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:7099, pubMedId:14500346, title:BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair., url:http://www.ncbi.nlm.nih.gov/pubmed/14500346]]]], position:587], [id:29445, fullName:BRAF G464X, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF G464X indicates any Braf missense mutation that results in replacement of the glycine (G) at amino acid 464 by a different amino acid., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:464], [id:3141, fullName:BRAF H608R, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF H608R lies within the protein kinase domain of the Braf protein (UniProt.org). H608R has been identified in sequencing studies (PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:7101, pubMedId:15331929, title:B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome., url:http://www.ncbi.nlm.nih.gov/pubmed/15331929]]]], position:608], [id:23112, fullName:BRAF E501G, impact:missense, proteinEffect:loss of function, geneVariantDescriptions:[[description:BRAF E501G lies within the protein kinase domain of the Braf protein (UniProt.org). E501G confers a loss of function to the Braf protein as demonstrated by inability to activate downstream reporter assays, impaired kinase activity and presence in genetic diseases associated with Ras/Raf/Mek dysfunction (PMID: 26065894, PMID: 16474404, PMID: 16439621)., references:[[id:5844, pubMedId:16474404, title:Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome., url:http://www.ncbi.nlm.nih.gov/pubmed/16474404], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:5843, pubMedId:26065894, title:Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation., url:http://www.ncbi.nlm.nih.gov/pubmed/26065894], [id:5839, pubMedId:16439621, title:Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome., url:http://www.ncbi.nlm.nih.gov/pubmed/16439621]]]], position:501], [id:29490, fullName:BRAF N486_A489delinsK, impact:indel, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF N486_A489delinsK results in a deletion of 4 amino acids in the protein kinase domain of the Braf protein from amino acids 486 to 489, combined with the insertion of a lysine (K) at the same site (UniProt.org). N486_A489delinsK has been identified in sequencing studies (PMID: 29247016), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Feb 2019)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:10750, pubMedId:29247016, title:Accelerating Discovery of Functional Mutant Alleles in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29247016], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed]]]], position:486], [id:13400, fullName:BRAF A598T, impact:missense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF A598T lies within the protein kinase domain of the Braf protein (UniProt.org). A598T demonstrates a lack of Braf kinase activity in culture (PMID: 22926515), and therefore, is predicted to result in a loss of Braf protein function., references:[[id:463, pubMedId:22926515, title:ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers., url:http://www.ncbi.nlm.nih.gov/pubmed/22926515], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:598], [id:1791, fullName:BRAF G464E, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF G464E (also reported as G463E) lies within the protein kinase domain of the Braf protein (UniProt.org). G464E results in increased Braf kinase activity and activation of MEK and ERK (PMID: 15035987, PMID: 23680146), and in one of two cell lines, increased cell proliferation and cell viability compared to wild-type Braf in culture (PMID: 29533785)., references:[[id:146, pubMedId:15035987, title:Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., url:http://www.ncbi.nlm.nih.gov/pubmed/15035987], [id:5858, pubMedId:23680146, title:RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation., url:http://www.ncbi.nlm.nih.gov/pubmed/23680146], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:464], [id:29627, fullName:BRAF V47_G327del, impact:deletion, proteinEffect:gain of function - predicted, geneVariantDescriptions:[[description:BRAF V47_G327del results in the deletion of 281 amino acids of the Braf protein from amino acids 47 to 327 (UniProt.org). V47_G327del (reported as internal deletion of exons 2-7) has not been characterized, however, due to the deletion of the CR1 autoinhibitory domain and preservation of the protein kinase domain (PMID: 23890088, PMID: 22113612, PMID: 29171936), V47_G327del is predicted to lead to a gain of Braf protein function., references:[[id:3413, pubMedId:23890088, title:Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy., url:http://www.ncbi.nlm.nih.gov/pubmed/23890088], [id:14626, pubMedId:22113612, title:RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)., url:http://www.ncbi.nlm.nih.gov/pubmed/22113612], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:14627, pubMedId:29171936, title:BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy., url:http://www.ncbi.nlm.nih.gov/pubmed/29171936]]]], position:47], [id:23123, fullName:BRAF G596V, impact:missense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF G596V lies within the protein kinase domain of the Braf protein (UniProt.org). G596V results in impaired Braf kinase activity and does not activate downstream MEK and ERK in cell culture (PMID: 16439621), but leads to activation of ERK in zebrafish models (PMID: 19376813), and is therefore predicted to lead to a loss of Braf protein function., references:[[id:5839, pubMedId:16439621, title:Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome., url:http://www.ncbi.nlm.nih.gov/pubmed/16439621], [id:5856, pubMedId:19376813, title:Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors., url:http://www.ncbi.nlm.nih.gov/pubmed/19376813], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:596], [id:900, fullName:BRAF L597R, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF L597R lies within the protein kinase domain of the Braf protein (UniProt.org). L597R results in activation of Braf as indicated by increased phosphorylation of Mek and Erk in cell culture (PMID: 22798288, PMID: 26343582), is associated with Erk activation in a patient tumor sample (PMID: 23715574), and in one of two cell lines, increased cell proliferation and cell viability compared to wild-type Braf (PMID: 29533785)., references:[[id:12177, pubMedId:23715574, title:Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma., url:http://www.ncbi.nlm.nih.gov/pubmed/23715574], [id:3, pubMedId:22798288, title:BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors., url:http://www.ncbi.nlm.nih.gov/pubmed/22798288], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:7141, pubMedId:26343582, title:BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition., url:http://www.ncbi.nlm.nih.gov/pubmed/26343582]]]], position:597], [id:28208, fullName:BRAF P367S, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF P367S does not lie within any known functional domains of the Braf protein (UniProt.org). P367S results in increased transformation ability compared to wild-type Braf in one of two cell lines in culture (PMID: 29533785), but  has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:367], [id:5048, fullName:BRAF W604R, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF W604R lies within the protein kinase domain of the Braf protein (UniProt.org). W604R has been identified in sequencing studies (PMID: 28188106, PMID: 21825258, PMID: 23833300), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:7103, pubMedId:21825258, title:Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations., url:http://www.ncbi.nlm.nih.gov/pubmed/21825258], [id:13418, pubMedId:28188106, title:Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial., url:http://www.ncbi.nlm.nih.gov/pubmed/28188106], [id:5855, pubMedId:23833300, title:Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/23833300]]]], position:604], [id:3123, fullName:BRAF A598_T599insV, impact:insertion, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF A598_T599insV results in the insertion of a valine (V) in the protein kinase domain of the Braf protein between amino acids 598 and 599 (UniProt.org). A598_T599insV results in increased Braf kinase activity, increased downstream Mapk and Mek signaling, and the ability to transform cells in culture (PMID: 16501605)., references:[[id:1892, pubMedId:16501605, title:Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma., url:http://www.ncbi.nlm.nih.gov/pubmed/16501605], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:598], [id:29453, fullName:BRAF F595X, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF F595X indicates any Braf missense mutation that results in replacement of the phenylalanine (F) at amino acid 595 by a different amino acid., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:595], [id:27732, fullName:BRAF V504I, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF V504I lies within the protein kinase domain of the Braf protein (UniProt.org). V504I has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Braf (PMID: 29533785)., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:504], [id:4988, fullName:BRAF G606V, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF G606V lies within the protein kinase domain of the Braf protein (UniProt.org). G606V has been identified in sequencing studies (PMID: 21825258), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:7103, pubMedId:21825258, title:Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations., url:http://www.ncbi.nlm.nih.gov/pubmed/21825258], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:606], [id:370, fullName:BRAF mutant, impact:unknown, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF mutant indicates an unspecified mutation in the BRAF gene., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:null], [id:27704, fullName:BRAF F259L, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF F259L lies within the protein kinase domain of the Braf protein (UniProt.org). F259L has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:259], [id:3140, fullName:BRAF G606E, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF G606E lies within the protein kinase domain of the Braf protein (UniProt.org). G606E has been identified in sequencing studies (PMID: 29320312, PMID: 28936923, PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:7101, pubMedId:15331929, title:B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome., url:http://www.ncbi.nlm.nih.gov/pubmed/15331929], [id:11783, pubMedId:28936923, title:EGFR pathway subgroups in Chilean colorectal cancer patients, detected by mutational and expression profiles, associated to different clinicopathological features., url:http://www.ncbi.nlm.nih.gov/pubmed/28936923], [id:13171, pubMedId:29320312, title:Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study., url:http://www.ncbi.nlm.nih.gov/pubmed/29320312]]]], position:606], [id:29576, fullName:BRAF S605E, impact:missense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF S605E lies within the protein kinase domain of the Braf protein (UniProt.org). S605E results in basal Mek phosphorylation similar to wild-type Braf but moderately decreased Mek phosphorylation upon Ras activation in culture (PMID: 27034005), and therefore, is predicted to lead to a loss of Braf protein function., references:[[id:14533, pubMedId:27034005, title:Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles., url:http://www.ncbi.nlm.nih.gov/pubmed/27034005], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:605], [id:29575, fullName:BRAF S605A, impact:missense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF S605A lies within the protein kinase domain of the Braf protein (UniProt.org). S605A results in basal Mek phosphorylation similar to wild-type Braf but moderately decreased Mek phosphorylation upon Ras activation in culture (PMID: 27034005), and therefore, is predicted to lead to a loss of Braf protein function., references:[[id:14533, pubMedId:27034005, title:Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles., url:http://www.ncbi.nlm.nih.gov/pubmed/27034005], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:605], [id:24559, fullName:BRAF dec exp, impact:none, proteinEffect:no effect, geneVariantDescriptions:[[description:BRAF dec exp indicates decreased expression of the Braf protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:null], [id:28188, fullName:BRAF E695K, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF E695K lies within the protein kinase domain of the Braf protein (UniProt.org). E695K has not been biochemically characterized, but results in increased transformation ability compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:695], [id:2592, fullName:BRAF K601I, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF K601I lies within the protein kinase domain of the Braf protein (UniProt.org). K601I has been identified in the scientific literature (PMID: 26682952, PMID: 29176861, PMID: 23555633), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:14455, pubMedId:26682952, title:Using "residual" FNA rinse and body fluid specimens for next-generation sequencing: An institutional experience., url:http://www.ncbi.nlm.nih.gov/pubmed/26682952], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:14454, pubMedId:29176861, title:Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma., url:http://www.ncbi.nlm.nih.gov/pubmed/29176861], [id:12138, pubMedId:23555633, title:Automated universal BRAF state detection within the activation segment in skin metastases by pyrosequencing-based assay U-BRAF(V600)., url:http://www.ncbi.nlm.nih.gov/pubmed/23555633]]]], position:601], [id:899, fullName:BRAF D594E, impact:missense, proteinEffect:loss of function, geneVariantDescriptions:[[description:BRAF D594E lies within the protein kinase domain of the Braf protein (UniProt.org). D594E results in impaired Braf kinase activity, however, results in increased Mek and Erk phosphorylation in the presence of CRAF in cell culture (PMID: 28783719)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:9692, pubMedId:28783719, title:Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., url:http://www.ncbi.nlm.nih.gov/pubmed/28783719]]]], position:594], [id:3162, fullName:BRAF S605G, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF S605G lies within the protein kinase domain of the Braf protein (UniProt.org). S605G results in basal Mek phosphorylation similar to wild-type Braf but moderately decreased Mek phosphorylation upon Ras activation in culture (PMID: 27034005), and therefore, is predicted to lead to a loss of Braf protein function., references:[[id:14533, pubMedId:27034005, title:Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles., url:http://www.ncbi.nlm.nih.gov/pubmed/27034005], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:605], [id:28206, fullName:BRAF N486D, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF N486D lies within the protein kinase domain of the Braf protein (UniProt.org). N486D results in increased transformation ability compared to wild-type Braf in one of two cell lines in culture (PMID: 29533785), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:486], [id:26917, fullName:BRAF S467L, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF S467L lies within the protein kinase domain of the Braf protein (UniProt.org). S467L results in impaired Braf kinase activity, but leads to Ras-dependent activation of Erk in cell culture (PMID: 28783719), and in two different cell lines, S467L increased cell proliferation and cell viability as compared to wild-type Braf (PMID: 29533785), and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:9692, pubMedId:28783719, title:Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., url:http://www.ncbi.nlm.nih.gov/pubmed/28783719]]]], position:467], [id:22991, fullName:BRAF R509H, impact:missense, proteinEffect:loss of function, geneVariantDescriptions:[[description:BRAF R509H lies within the dimerization interface region of the Braf protein (PMID: 22510884). R509H confers a loss of function to the Braf protein, as demonstrated by decreased Braf dimerization and reduced ability to activate downstream Mek signaling in in vitro assays (PMID: 22510884)., references:[[id:5712, pubMedId:22510884, title:Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling., url:http://www.ncbi.nlm.nih.gov/pubmed/22510884]]]], position:509], [id:25028, fullName:BRAF Q257H, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF Q257H lies within the Phorbol-ester/DAG-type zinc finger region of the Braf protein (UniProt.org). Q257H has been identified in sequencing studies (PMID: 28852190, PMID: 27147599), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019). 
, references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11143, pubMedId:28852190, title:Mutational heterogeneity in non-serous ovarian cancers., url:http://www.ncbi.nlm.nih.gov/pubmed/28852190], [id:6273, pubMedId:27147599, title:Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles., url:http://www.ncbi.nlm.nih.gov/pubmed/27147599], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed]]]], position:257], [id:3148, fullName:BRAF K601del, impact:deletion, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF K601del results in the deletion of one amino acid in the protein kinase domain of the Braf protein at amino acid 601 (UniProt.org). K601del has been identified in sequencing studies (PMID: 19152441), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:7105, pubMedId:19152441, title:High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes., url:http://www.ncbi.nlm.nih.gov/pubmed/19152441], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:601], [id:27715, fullName:BRAF P341S, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF P341S lies within the protein kinase domain of the Braf protein (UniProt.org). P341S has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:341], [id:28592, fullName:BRAF P367R, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF P367R does not lie within any known functional domains within the Braf protein (UniProt.org). P367R confers a gain of function to the Braf protein as indicated by increased Erk phosphorylation in culture and tumor formation in animal models, and demonstrates resistance to Egfr inhibitors in culture (PMID: 27478040)., references:[[id:8124, pubMedId:27478040, title:High-throughput Phenotyping of Lung Cancer Somatic Mutations., url:http://www.ncbi.nlm.nih.gov/pubmed/27478040], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:367], [id:4985, fullName:BRAF G469L, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF G469L is a hotspot mutation lies within the protein kinase domain of the Braf protein (UniProt.org). G469L has been identified in the scientific literature (PMID: 24035431, PMID: 26301799, PMID: 26200454), but has not been biochemically characterized, and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:7321, pubMedId:24035431, title:Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib., url:http://www.ncbi.nlm.nih.gov/pubmed/24035431], [id:12131, pubMedId:26301799, title:BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/26301799], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:14438, pubMedId:26200454, title:Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort., url:http://www.ncbi.nlm.nih.gov/pubmed/26200454]]]], position:469], [id:28193, fullName:BRAF G615R, impact:missense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF G615R lies within the protein kinase domain of the Braf protein (UniProt.org). G615R has not been biochemically characterized, but demonstrates decreased transformation ability in cell culture (PMID: 29533785), and is therefore predicted to confer a loss of function to the Braf protein., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:615], [id:3590, fullName:BRAF V600_K601delinsE, impact:indel, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF V600_K601delinsE results in the deletion of two amino acids formation of a new glutamic acid (E) residue in the protein kinase domain of the Braf protein between amino acids 600 and 601 (UniProt.org, PMID: 22563563). V600_K601delinsE leads to activation of downstream Mek and Erk signaling, increased colony formation (PMID: 17297294), and induces cell proliferation and cell viability in cell culture (PMID: 29533785)., references:[[id:2112, pubMedId:17297294, title:Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/17297294], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:2113, pubMedId:22563563, title:Identification of a rare 3 bp BRAF gene deletion in a thyroid nodule by mutant enrichment with 3'-modified oligonucleotides polymerase chain reaction., url:http://www.ncbi.nlm.nih.gov/pubmed/22563563]]]], position:600], [id:23126, fullName:BRAF N581D, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF N581D lies within the protein kinase domain of the Braf protein (UniProt.org). N581D results in transactivation of ELK at comparable levels to wild-type Braf in a reporter assay (PMID: 16474404), and is therefore predicted to have no effect on Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:5844, pubMedId:16474404, title:Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome., url:http://www.ncbi.nlm.nih.gov/pubmed/16474404]]]], position:581], [id:28194, fullName:BRAF G69S, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF G69S does not lie within any known functional domains of the Braf protein (UniProt.org). G69S results in increased transformation ability compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:69], [id:5045, fullName:BRAF V471I, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF V471I lies within the protein kinase domain of the Braf protein (UniProt.org). V471I has been identified in sequencing studies (PMID: 28188106, PMID: 23103869), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:6989, pubMedId:23103869, title:Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes., url:http://www.ncbi.nlm.nih.gov/pubmed/23103869], [id:13418, pubMedId:28188106, title:Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial., url:http://www.ncbi.nlm.nih.gov/pubmed/28188106]]]], position:471], [id:23124, fullName:BRAF K483M, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF K483M (also reported as K482M) lies within an ATP binding site in the protein kinase domain of the Braf protein (UniProt.org). K483M results in a loss of Braf kinase activity, however, has been demonstrated to both activate MEK through CRAF (PMID: 16508002, PMID: 23533272), and lack ability to activate ERK and CRAF in cell culture and in Xenopus (PMID: 15035987), and therefore, its effect on Braf protein function is unknown., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:2256, pubMedId:23533272, title:Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas., url:http://www.ncbi.nlm.nih.gov/pubmed/23533272], [id:9727, pubMedId:16508002, title:Regulation and role of Raf-1/B-Raf heterodimerization., url:http://www.ncbi.nlm.nih.gov/pubmed/16508002]]]], position:483], [id:3518, fullName:BRAF I463S, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF I463S lies within the protein kinase domain of the Braf protein (UniProt.org). I463S results in an intermediate increase in Braf kinase activity compared to wild-type Braf and increased Erk activation in cell culture (PMID: 15035987)., references:[[id:146, pubMedId:15035987, title:Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., url:http://www.ncbi.nlm.nih.gov/pubmed/15035987], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:463], [id:5046, fullName:BRAF V600fs, impact:frameshift, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF V600fs results in a change in the amino acid sequence of the Braf protein beginning at aa 600 of 766, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the disruption of the protein kinase domain, V600fs is predicted to lead to a loss of Braf protein function (UniProt.org)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:600], [id:3152, fullName:BRAF P453T, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF P453T does not lie within any known functional domains of the Braf protein (UniProt.org). P453T has been identified in sequencing studies (PMID: 27717198, PMID: 16404419), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:14452, pubMedId:27717198, title:Young investigator challenge: Can the Ion AmpliSeq Cancer Hotspot Panel v2 be used for next-generation sequencing of thyroid FNA samples?, url:http://www.ncbi.nlm.nih.gov/pubmed/27717198], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:7110, pubMedId:16404419, title:BRAF mutations and phosphorylation status of mitogen-activated protein kinases in the development of flat and depressed-type colorectal neoplasias., url:http://www.ncbi.nlm.nih.gov/pubmed/16404419], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:453], [id:3519, fullName:BRAF N581S, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF N581S lies within the protein kinase domain of the Braf protein (UniProt.org). The functional effect of N581S is unclear as it has been demonstrated to result in intermediate Braf kinase activity (PMID: 15035987), as well as low Braf kinase activity (PMID: 28783719), and results in Ras-dependent activation of ERK signaling in cell culture (PMID: 28783719), however in another study, N581S demonstrated increased transformation ability in one of two different cell lines as compared to wild-type Braf (PMID: 29533785)., references:[[id:146, pubMedId:15035987, title:Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., url:http://www.ncbi.nlm.nih.gov/pubmed/15035987], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:9692, pubMedId:28783719, title:Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., url:http://www.ncbi.nlm.nih.gov/pubmed/28783719], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:581], [id:3179, fullName:BRAF V600delinsYM, impact:indel, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF V600delinsYM results in a deletion of valine (V) at amino acid 600 within the protein kinase domain of the Braf protein, combined with the insertion of a tyrosine (Y) and a methionine (M) at the same site (UniProt.org). V600delinsYM results in increased Braf kinase activity, increased downstream signaling, and the ability to transform cells in culture (PMID: 22752848)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:1912, pubMedId:22752848, title:Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma., url:http://www.ncbi.nlm.nih.gov/pubmed/22752848]]]], position:600], [id:29625, fullName:BRAF V169_G327del, impact:deletion, proteinEffect:gain of function - predicted, geneVariantDescriptions:[[description:BRAF V169_G327del results in the deletion of 159 amino acids of the Braf protein from amino acids 169 to 327 (UniProt.org). V169_G327del (reported as internal deletion of exons 4-7) has not been characterized, however, due to the deletion of the CR1 autoinhibitory domain and preservation of the protein kinase domain (PMID: 23890088, PMID: 22113612, PMID: 29171936), V169_G327del is predicted to lead to a gain of Braf protein function., references:[[id:14626, pubMedId:22113612, title:RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)., url:http://www.ncbi.nlm.nih.gov/pubmed/22113612], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:3413, pubMedId:23890088, title:Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy., url:http://www.ncbi.nlm.nih.gov/pubmed/23890088], [id:14627, pubMedId:29171936, title:BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy., url:http://www.ncbi.nlm.nih.gov/pubmed/29171936]]]], position:169], [id:29628, fullName:BRAF G203_G393del, impact:deletion, proteinEffect:gain of function - predicted, geneVariantDescriptions:[[description:BRAF G203_G393del results in the deletion of 91 amino acids of the Braf protein from amino acids 203 to 393 (UniProt.org). G203_G393del (reported as internal deletion of exons 5-9) has not been characterized, however, due to the disruption of the CR1 autoinhibitory domain and preservation of the protein kinase domain (PMID: 23890088, PMID: 22113612, PMID: 29171936), G203_G393del is predicted to lead to a gain of Braf protein function., references:[[id:3413, pubMedId:23890088, title:Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy., url:http://www.ncbi.nlm.nih.gov/pubmed/23890088], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:14626, pubMedId:22113612, title:RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)., url:http://www.ncbi.nlm.nih.gov/pubmed/22113612], [id:14627, pubMedId:29171936, title:BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy., url:http://www.ncbi.nlm.nih.gov/pubmed/29171936]]]], position:203], [id:27703, fullName:BRAF E228V, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF E228V lies within the protein kinase domain of the Braf protein (UniProt.org). E228V has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:228], [id:29441, fullName:BRAF Q257X, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF Q257X indicates any Braf missense mutation that results in replacement of the glutamine (Q) at amino acid 257 by a different amino acid., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:257], [id:1790, fullName:BRAF G469V, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF G469V is a hotspot mutation within the protein kinase domain of the Braf protein (UniProt.org). G469V results in increased Braf kinase activity and activation of downstream MEK and ERK in cell culture (PMID: 28947956, PMID: 26343582, PMID: 28783719), and in one of two cell lines, increased cell proliferation and cell viability compared to wild-type Braf (PMID: 29533785)., references:[[id:9692, pubMedId:28783719, title:Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., url:http://www.ncbi.nlm.nih.gov/pubmed/28783719], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:7141, pubMedId:26343582, title:BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition., url:http://www.ncbi.nlm.nih.gov/pubmed/26343582], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:12147, pubMedId:28947956, title:Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib., url:http://www.ncbi.nlm.nih.gov/pubmed/28947956]]]], position:469], [id:27719, fullName:BRAF Q609H, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF Q609H lies within the protein kinase domain of the Braf protein (UniProt.org). Q609H has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:609], [id:470, fullName:BRAF G466V, impact:missense, proteinEffect:loss of function, geneVariantDescriptions:[[description:BRAF G466V lies within the protein kinase domain of the Braf protein (UniProt.org). G466V results in impaired Braf kinase activity, but paradoxically activates MEK and ERK through transactivation of CRAF in cell culture (PMID: 22649091, PMID: 28783719), and in one of two cell lines, G466V decreased cell proliferation and cell viability as compared to wild-type Braf (PMID: 29533785)., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:9692, pubMedId:28783719, title:Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., url:http://www.ncbi.nlm.nih.gov/pubmed/28783719], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:423, pubMedId:22649091, title:Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib., url:http://www.ncbi.nlm.nih.gov/pubmed/22649091]]]], position:466], [id:29489, fullName:BRAF P367L, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF P367L does not lie within any known functional domains of the Braf protein (UniProt.org). P367L has been identified in sequencing studies (PMID: 26317466), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Feb 2019)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:14317, pubMedId:26317466, title:Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses., url:http://www.ncbi.nlm.nih.gov/pubmed/26317466], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed]]]], position:367], [id:26677, fullName:BRAF F247L, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF F247L lies within the phorbol-ester/DAG-type zinc finger region of the Braf protein (UniProt.org). F247L confers a gain of function to Braf, as indicated by activation of downstream MAPK signaling and is transforming in cultured cells (PMID: 28512244, PMID: 29533785)., references:[[id:9257, pubMedId:28512244, title:Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/28512244], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:247], [id:29448, fullName:BRAF G469X, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF G469X indicates any Braf missense mutation that results in replacement of the glycine (G) at amino acid 469 by a different amino acid., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:469], [id:464, fullName:BRAF L597V, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF L597V lies within the protein kinase domain of the Braf protein (UniProt.org). L597V results in activation of Braf as indicated by increased phosphorylation of Mek and Erk in cell culture (PMID: 22798288) and and induces cell proliferation and cell viability in culture (PMID: 29533785)., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:3, pubMedId:22798288, title:BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors., url:http://www.ncbi.nlm.nih.gov/pubmed/22798288]]]], position:597], [id:13, fullName:BRAF wild-type, impact:none, proteinEffect:no effect, geneVariantDescriptions:[[description:Wild-type BRAF indicates that no mutation has been detected within the BRAF gene., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:null], [id:29614, fullName:BRAF V47_M438del, impact:deletion, proteinEffect:gain of function - predicted, geneVariantDescriptions:[[description:BRAF V47_M438del results in the deletion of 392 amino acids of the Braf protein from amino acids 47 to 438 (UniProt.org). V47_M438del (reported as internal deletion of exons 2-10) has not been characterized, however, due to the deletion of the CR1 autoinhibitory domain and preservation of the protein kinase domain (PMID: 23890088, PMID: 22113612, PMID: 29171936), V47_M438del is predicted to lead to a gain of Braf protein function., references:[[id:14627, pubMedId:29171936, title:BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy., url:http://www.ncbi.nlm.nih.gov/pubmed/29171936], [id:3413, pubMedId:23890088, title:Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy., url:http://www.ncbi.nlm.nih.gov/pubmed/23890088], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:14626, pubMedId:22113612, title:RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)., url:http://www.ncbi.nlm.nih.gov/pubmed/22113612]]]], position:47], [id:29450, fullName:BRAF N581X, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF N581X indicates any Braf missense mutation that results in replacement of the asparagine (N) at amino acid 581 by a different amino acid., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:581], [id:29444, fullName:BRAF I463X, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF I463X indicates any Braf missense mutation that results in replacement of the isoleucine (I) at amino acid 463 by a different amino acid., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:463], [id:1792, fullName:BRAF E275K, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF E275K lies within the phorbol-ester/DAG-type zinc finger region of the Braf protein (UniProt.org). E275K results in decreased activation of Mek and Erk (PMID: 19206169), but also demonstrates similar cell proliferation and viability as compared to wild-type Braf in culture (PMID: 29533785), and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:760, pubMedId:19206169, title:Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum., url:http://www.ncbi.nlm.nih.gov/pubmed/19206169], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:275], [id:29579, fullName:BRAF S465E, impact:missense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF S465E lies within the protein kinase domain of the Braf protein (UniProt.org). S465E results in basal Mek phosphorylation similar to wild-type Braf but decreased Mek phosphorylation upon Ras activation in culture (PMID: 27034005), and therefore, is predicted to lead to a loss of Braf protein function., references:[[id:14533, pubMedId:27034005, title:Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles., url:http://www.ncbi.nlm.nih.gov/pubmed/27034005], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:465], [id:28195, fullName:BRAF H269Y, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF H269Y lies within the Phorbol-ester/DAG-type zinc finger domain of the Braf protein (UniProt.org). H269Y has not been biochemically characterized, but results in increased transformation ability compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:269], [id:2662, fullName:BRAF W619R, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF W619R lies within the protein kinase domain of the Braf protein (UniProt.org). W619R has been identified in sequencing studies (PMID: 16179870), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:7114, pubMedId:16179870, title:Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases., url:http://www.ncbi.nlm.nih.gov/pubmed/16179870]]]], position:619], [id:28285, fullName:BRAF H568D, impact:missense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF H568D lies within the protein kinase domain of the Braf protein (UniProt.org). H568D results in a loss of MEK phosphorylation in cell culture similar to Braf kinase-dead variants (PMID: 29666306), and therefore, is predicted to confer a loss of function to the Braf protein., references:[[id:11355, pubMedId:29666306, title:Truncation- and motif-based pan-cancer analysis reveals tumor-suppressing kinases., url:http://www.ncbi.nlm.nih.gov/pubmed/29666306], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:568], [id:2634, fullName:BRAF T599R, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF T599R lies within the activation loop in the kinase domain of the Braf protein (PMID: 19206169). T599R confers a gain of function on Braf, as indicated by increased MEK and ERK phosphorylation, and is transforming in cell culture (PMID: 19206169, PMID: 29533785)., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:760, pubMedId:19206169, title:Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum., url:http://www.ncbi.nlm.nih.gov/pubmed/19206169]]]], position:599], [id:29613, fullName:BRAF N486_T491delinsK, impact:indel, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF N486_T491delinsK results in a deletion of 6 amino acids in the protein kinase domain of the Braf protein from amino acids 486 to 491, combined with the insertion of a lysine (K) at the same site (UniProt.org). N486_A491delinsK confers a gain of function to Braf, as indicated by increased ERK activation and transformation of cultured cells (PMID: 30867592)., references:[[id:14632, pubMedId:30867592, title:Efficacy of MEK inhibition in patients with histiocytic neoplasms., url:http://www.ncbi.nlm.nih.gov/pubmed/30867592], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:486], [id:29456, fullName:BRAF A598X, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF A598X indicates any Braf missense mutation that results in replacement of the alanine (A) at amino acid 598 by a different amino acid., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:598], [id:23121, fullName:BRAF G596C, impact:missense, proteinEffect:loss of function, geneVariantDescriptions:[[description:BRAF G596C lies within the protein kinase domain of the Braf protein (UniProt.org). G596C results in decreased Braf kinase activity, however, leads to activation of downstream MEK and ERK in combination with CRAF in cell culture (PMID: 28947956)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:12147, pubMedId:28947956, title:Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib., url:http://www.ncbi.nlm.nih.gov/pubmed/28947956]]]], position:596], [id:23132, fullName:BRAF Q257R, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF Q257R lies within the phorbol-ester/DAG-type zinc finger region of the BRAF protein (UniProt.org). Q257R confers a gain of function to the Braf protein as demonstrated by increased kinase activity and activation of downstream Mek signaling in cell cuture, and activation of ELK in reporter assays (PMID: 16474404, PMID: 16439621)., references:[[id:5839, pubMedId:16439621, title:Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome., url:http://www.ncbi.nlm.nih.gov/pubmed/16439621], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:5844, pubMedId:16474404, title:Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome., url:http://www.ncbi.nlm.nih.gov/pubmed/16474404]]]], position:257], [id:17026, fullName:BRAF Q262R, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF Q262R lies within the Phorbol-ester/DAG-type zinc finger region of the Braf protein (UniProt.org). Q262R has not been characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019).
, references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:262], [id:3139, fullName:BRAF G596D, impact:missense, proteinEffect:loss of function, geneVariantDescriptions:[[description:BRAF G596D lies within the protein kinase domain of the Braf protein (UniProt.org). G596D demonstrates decreased Braf kinase activity in cell culture (PMID: 28783719), and therefore is predicted to confer a loss of function to the Braf protein., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:9692, pubMedId:28783719, title:Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., url:http://www.ncbi.nlm.nih.gov/pubmed/28783719]]]], position:596], [id:19428, fullName:BRAF L485_P490delinsY, impact:indel, proteinEffect:gain of function - predicted, geneVariantDescriptions:[[description:BRAF L485_P490delinsY results in a deletion of six amino acids near the alphaC-helix region of the Braf protein kinase domain combined with the insertion of one new amino acid in the same location (PMID: 26732095). L485_P490delinsY is associated with increased MEK/ERK activation in cells also harboring L485_P490delinsF, and similar deletions result in Braf activation (PMID: 26732095), and therefore, L485_P490delinsY is predicted to confer a gain of function to the Braf protein., references:[[id:4801, pubMedId:26732095, title:Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120., url:http://www.ncbi.nlm.nih.gov/pubmed/26732095]]]], position:485], [id:2771, fullName:BRAF L505H, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF L505H lies within the protein kinase domain of the Braf protein (UniProt.org). L505H confers a gain of function to the Braf protein resulting in MEK/ERK activation and oncogenic transformation in cultured cells, and is associated with resistance to RAF inhibitors (PMID: 24283590)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:1371, pubMedId:24283590, title:Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors., url:http://www.ncbi.nlm.nih.gov/pubmed/24283590]]]], position:505], [id:28211, fullName:BRAF S607F, impact:missense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF S607F lies within the protein kinase domain of the Braf protein (UniProt.org). S607F has not been biochemically characterized, but demonstrates decreased transformation ability in cell culture (PMID: 29533785), and is therefore predicted to confer a loss of function to the Braf protein., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:607], [id:27708, fullName:BRAF K205Q, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF K205Q lies within the protein kinase domain of the Braf protein (UniProt.org). K205Q has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:205], [id:23134, fullName:BRAF S467A, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF S467A lies within the protein kinase domain of the Braf protein (UniProt.org). S467A confers a gain of function to the Braf protein as demonstrated by increased kinase activity and activation of downstream Mek signaling (PMID: 23680146, PMID: 16439621)., references:[[id:5858, pubMedId:23680146, title:RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation., url:http://www.ncbi.nlm.nih.gov/pubmed/23680146], [id:5839, pubMedId:16439621, title:Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome., url:http://www.ncbi.nlm.nih.gov/pubmed/16439621], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:467], [id:28205, fullName:BRAF M53I, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF M53I does not lie within any known functional domains of the Braf protein (UniProt.org). M53I results in increased transformation ability compared to wild-type Braf in one of two cell lines in culture (PMID: 29533785), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:53], [id:578, fullName:BRAF act mut, impact:unknown, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF act mut indicates that this variant results in a gain of function in the Braf protein. However, the specific amino acid change has not been identified., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:null], [id:29612, fullName:BRAF V169_D380del, impact:deletion, proteinEffect:gain of function - predicted, geneVariantDescriptions:[[description:BRAF V169_D380del results in the deletion of 212 amino acids of the Braf protein from amino acids 169 to 380 (UniProt.org). V169_D380del (reported as internal deletion of exons 4-8) has not been characterized, however, due to the deletion of the CR1 autoinhibitory domain and preservation of the protein kinase domain (PMID: 23890088, PMID: 22113612, PMID: 29171936), V169_D380del is predicted to lead to a gain of Braf protein function., references:[[id:3413, pubMedId:23890088, title:Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy., url:http://www.ncbi.nlm.nih.gov/pubmed/23890088], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:14626, pubMedId:22113612, title:RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)., url:http://www.ncbi.nlm.nih.gov/pubmed/22113612], [id:14627, pubMedId:29171936, title:BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy., url:http://www.ncbi.nlm.nih.gov/pubmed/29171936]]]], position:169], [id:27702, fullName:BRAF A320T, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF A320T lies within the protein kinase domain of the Braf protein (UniProt.org). A320T has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:320], [id:901, fullName:BRAF L597Q, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF L597Q lies within the protein kinase domain of the Braf protein (UniProt.org). L597Q results in activation of Braf as indicated by increased phosphorylation of Mek and Erk in cell culture (PMID: 22798288) and induces cell proliferation and cell viability in culture (PMID: 29533785)., references:[[id:3, pubMedId:22798288, title:BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors., url:http://www.ncbi.nlm.nih.gov/pubmed/22798288], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:597], [id:27006, fullName:BRAF I463T, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF I463T lies within the protein kinase domain of the Braf protein (UniProt.org). I463T has been identified in the scientific literature (PMID: 28829677), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:9957, pubMedId:28829677, title:BRAF mutation as a novel driver of eosinophilic cystitis., url:http://www.ncbi.nlm.nih.gov/pubmed/28829677], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed]]]], position:463], [id:1252, fullName:BRAF rearrange, impact:unknown, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF rearrangement indicates an unspecified rearrangement of the BRAF gene., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:null], [id:3172, fullName:BRAF S605N, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF S605N lies within the protein kinase domain of the Braf protein (UniProt.org). S605N has been identified in sequencing studies (PMID: 29176861, PMID: 28628916, PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:14453, pubMedId:28628916, title:Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536., url:http://www.ncbi.nlm.nih.gov/pubmed/28628916], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:7101, pubMedId:15331929, title:B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome., url:http://www.ncbi.nlm.nih.gov/pubmed/15331929], [id:14454, pubMedId:29176861, title:Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma., url:http://www.ncbi.nlm.nih.gov/pubmed/29176861]]]], position:605], [id:27701, fullName:BRAF D380H, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF D380H lies within the protein kinase domain of the Braf protein (UniProt.org). D380H has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:380], [id:25588, fullName:BRAF L485F, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF L485F lies within the protein kinase domain of the Braf protein (UniProt.org). L485F confers a gain of function to the Braf protein as demonstrated by increased kinase activity and activation of downstream Mek and Erk in cell culture (PMID: 16439621), and in one of two cell lines, L485F increased cell proliferation and cell viability compared to wild-type Braf (PMID: 29533785)., references:[[id:5839, pubMedId:16439621, title:Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome., url:http://www.ncbi.nlm.nih.gov/pubmed/16439621], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:485], [id:29442, fullName:BRAF P367X, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF P367X indicates any Braf missense mutation that results in replacement of the proline (P) at amino acid 367 by a different amino acid., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:367], [id:27731, fullName:BRAF T470K, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF T470K lies within the protein kinase domain of the Braf protein (UniProt.org). T470K has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:470], [id:17027, fullName:BRAF V226L, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF V226L lies within the Ras-binding domain of the Braf protein (UniProt.org). V226L has not been characterized in the scientific literature and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:226], [id:3766, fullName:BRAF K601T, impact:missense, proteinEffect:gain of function - predicted, geneVariantDescriptions:[[description:BRAF K601T lies within the activation segment in the kinase domain of the Braf protein (PMID: 15343278). K601T results in increased Braf kinase activity in cell culture (PMID: 28783719), and in one of two cell lines increased cell proliferation and cell viability compared to wild-type Braf (PMID: 29533785), and is therefore predicted to confer a gain of function to the Braf protein., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:9692, pubMedId:28783719, title:Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., url:http://www.ncbi.nlm.nih.gov/pubmed/28783719], [id:9694, pubMedId:15343278, title:Switching on kinases: oncogenic activation of BRAF and the PDGFR family., url:http://www.ncbi.nlm.nih.gov/pubmed/15343278]]]], position:601], [id:28669, fullName:BRAF V600dup, impact:duplication, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF V600dup (also referred to as T599_V600insV) indicates the insertion of the duplicate amino acid, valine (V)-600, in the protein kinase domain of the Braf protein (UniProt.org). V600dup confers a gain of function to the Braf protein as demonstrated by increased kinase activity and phosphorylation of downstream Mek and Erk, and is transforming in cell culture (PMID: 21190184)., references:[[id:1910, pubMedId:21190184, title:Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma., url:http://www.ncbi.nlm.nih.gov/pubmed/21190184], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:600], [id:452, fullName:BRAF G469A, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF G469A is a hotspot mutation within the protein kinase domain of the Braf protein (UniProt.org). G469A results in increased Braf kinase activity and downstream activation of Erk, and is transforming in cell culture (PMID: 19010912, PMID: 12068308, PMID: 29533785)., references:[[id:636, pubMedId:19010912, title:Genetic predictors of MEK dependence in non-small cell lung cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/19010912], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:637, pubMedId:12068308, title:Mutations of the BRAF gene in human cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/12068308], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:469], [id:3517, fullName:BRAF G466E, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF G466E lies within the protein kinase domain of the Braf protein (UniProt.org). G466E results in impaired Braf kinase activity, but paradoxically increases Erk signaling through C-raf activation in cell culture and Xenopus embryos (PMID: 15035987), however, induces similar cell proliferation and cell viability as wild-type Braf (PMID: 29533785), and therefore, its effect on Braf protein function is unknown., references:[[id:146, pubMedId:15035987, title:Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., url:http://www.ncbi.nlm.nih.gov/pubmed/15035987], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:466], [id:26912, fullName:BRAF D287H, impact:missense, proteinEffect:loss of function, geneVariantDescriptions:[[description:BRAF D287H does not lie within any known functional domains of the Braf protein (UniProt.org). D287H results in impaired Braf kinase activity, but leads to Ras-dependent activation of Erk in cell culture (PMID: 26343582, PMID: 28783719)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:7141, pubMedId:26343582, title:BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition., url:http://www.ncbi.nlm.nih.gov/pubmed/26343582], [id:9692, pubMedId:28783719, title:Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., url:http://www.ncbi.nlm.nih.gov/pubmed/28783719]]]], position:287], [id:3158, fullName:BRAF S605F, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF S605F lies within the protein kinase domain of the Braf protein (UniProt.org). S605F has been identified in sequencing studies (PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:7101, pubMedId:15331929, title:B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome., url:http://www.ncbi.nlm.nih.gov/pubmed/15331929]]]], position:605], [id:3183, fullName:BRAF V600Q, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF V600Q (previously reported as V599Q) lies within the activation segment and the protein kinase domain of the Braf protein (PMID: 15035987). V600Q has been identified in the scientific literature (PMID: 28848703), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:12140, pubMedId:28848703, title:BRAF V600Q-mutated lung adenocarcinoma with duodenal metastasis and extreme leukocytosis., url:http://www.ncbi.nlm.nih.gov/pubmed/28848703], [id:146, pubMedId:15035987, title:Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., url:http://www.ncbi.nlm.nih.gov/pubmed/15035987]]]], position:600], [id:27710, fullName:BRAF L64I, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF L64I lies within the protein kinase domain of the Braf protein (UniProt.org). L64I has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:64], [id:28199, fullName:BRAF K499N, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF K499N lies within the protein kinase domain of the Braf protein (UniProt.org). K449N results in increased transformation ability compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:499], [id:29620, fullName:BRAF A81_D380del, impact:deletion, proteinEffect:gain of function - predicted, geneVariantDescriptions:[[description:BRAF A81_D380del results in the deletion of 300 amino acids of the Braf protein from amino acids 81 to 380 (UniProt.org). A81_D380del (reported as internal deletion of exons 3-8) has not been characterized, however, due to the deletion of the CR1 autoinhibitory domain and preservation of the protein kinase domain (PMID: 23890088, PMID: 22113612, PMID: 29171936), A81_D380del is predicted to lead to a gain of Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:14626, pubMedId:22113612, title:RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)., url:http://www.ncbi.nlm.nih.gov/pubmed/22113612], [id:14627, pubMedId:29171936, title:BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy., url:http://www.ncbi.nlm.nih.gov/pubmed/29171936], [id:3413, pubMedId:23890088, title:Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy., url:http://www.ncbi.nlm.nih.gov/pubmed/23890088]]]], position:81], [id:29492, fullName:BRAF K601_S602delinsNT, impact:indel, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF K601_S602delinsNT results in a deletion of two amino acids in the protein kinase domain of the Braf protein from amino acids 601 to 602, combined with the insertion of an asparagine (N) and a threonine (T) at the same site (UniProt.org). K601_S602delinsNT has not been characterized and therefore, its effect on Braf protein function is unknown (PubMed, Feb 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:601], [id:27729, fullName:BRAF S637*, impact:nonsense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF S637* results in a premature truncation the Braf protein at amino acid 637 of 766 (UniProt.org). S637* has not been biochemically characterized, however, demonstrates an inability to induce cell viability and proliferation in cell culture (PMID: 29533785), and therefore is predicted to confer a loss of function to the Braf protein., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:637], [id:404, fullName:BRAF V600E/K, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF V600E/K indicates a mutation that results in the replacement of the valine (V) at amino acid 600 of the Braf protein by either a glutamate (E) or lysine (K). V600E/K mutations are hotspot mutations in Braf that result in increased Braf kinase activity (PMID: 15035987)., references:[[id:146, pubMedId:15035987, title:Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., url:http://www.ncbi.nlm.nih.gov/pubmed/15035987]]]], position:600], [id:2561, fullName:BRAF G596R, impact:missense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF G596R lies within the protein kinase domain of the Braf protein, within the DFG motif (PMID: 19735675). G596R results in impaired Braf kinase activity and decreased Mek and Erk phosphorylation, including in the presence of BRAF V600E, is not transforming in culture and does not promote tumor formation in mouse models, but results in activation of Erk in the presence of CRAF (PMID: 19735675, PMID: 28783719), however, in another study demonstrates similar cell proliferation and viability levels to wild-type Braf (PMID: 29533785), and is predicted to confer a loss of function to the Braf protein., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:9692, pubMedId:28783719, title:Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., url:http://www.ncbi.nlm.nih.gov/pubmed/28783719], [id:1060, pubMedId:19735675, title:Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif., url:http://www.ncbi.nlm.nih.gov/pubmed/19735675]]]], position:596], [id:3176, fullName:BRAF T599_V600insTT, impact:insertion, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF T599_V600insTT results in the insertion of two threonines (T) in the protein kinase domain of the Braf protein between amino acids 599 and 600 (UniProt.org). T599_V600insTT results in increased Braf kinase activity in an in vitro assay, and increased downstream Mek/Erk signaling in culture (PMID: 21190184)., references:[[id:1910, pubMedId:21190184, title:Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma., url:http://www.ncbi.nlm.nih.gov/pubmed/21190184], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:599], [id:4989, fullName:BRAF L597P, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF L597P lies within the protein kinase domain of the Braf protein (UniProt.org). L597P has been identified in sequencing studies (PMID: 30268455, PMID: 24714776), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:14442, pubMedId:30268455, title:Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA., url:http://www.ncbi.nlm.nih.gov/pubmed/30268455], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:12139, pubMedId:24714776, title:Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib., url:http://www.ncbi.nlm.nih.gov/pubmed/24714776], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:597], [id:27727, fullName:BRAF S419Y, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF S419Y lies within the protein kinase domain of the Braf protein (UniProt.org). S419Y has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:419], [id:50, fullName:BRAF V600K, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF V600K (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600K confers a gain of function to the Braf protein as demonstrated by increased kinase activity, downstream signaling, and the ability to transform cells in vitro (PMID: 15035987, PMID: 29533785)., references:[[id:146, pubMedId:15035987, title:Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., url:http://www.ncbi.nlm.nih.gov/pubmed/15035987], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:600], [id:28198, fullName:BRAF K483E, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF K483E lies within the protein kinase domain of the Braf protein (UniProt.org). K483E results in increased transformation compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), but also results in ERK1/2 phosphorylation level similar to wild-type Braf in culture (PMID: 27799065), and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:14477, pubMedId:27799065, title:A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma., url:http://www.ncbi.nlm.nih.gov/pubmed/27799065], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:483], [id:28591, fullName:BRAF H574N, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF H574N lies within the protein kinase domain of the Braf protein (UniProt.org). H574N results in Erk phosphorylation at similar levels to wild-type Braf in culture (PMID: 27478040), and is therefore predicted to have no effect on Braf protein function., references:[[id:8124, pubMedId:27478040, title:High-throughput Phenotyping of Lung Cancer Somatic Mutations., url:http://www.ncbi.nlm.nih.gov/pubmed/27478040], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:574], [id:893, fullName:BRAF V600M, impact:missense, proteinEffect:gain of function - predicted, geneVariantDescriptions:[[description:BRAF V600M (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600M results in intermediate Braf kinase activity in cell culture (PMID: 28783719), and in one of two cell lines increased cell proliferation and cell viability compared to wild-type Braf (PMID: 29533785), and is therefore predicted to confer a gain of function to the Braf protein., references:[[id:9692, pubMedId:28783719, title:Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., url:http://www.ncbi.nlm.nih.gov/pubmed/28783719], [id:146, pubMedId:15035987, title:Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., url:http://www.ncbi.nlm.nih.gov/pubmed/15035987], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:600], [id:23130, fullName:BRAF L485_Q494del, impact:deletion, proteinEffect:gain of function - predicted, geneVariantDescriptions:[[description:BRAF L485_Q494del results in the deletion of ten amino acids within the beta-3/alpha-C helix loop in the protein kinase domain of the Braf protein (PMID: 26732095, UniProt.org). L485_Q494del has not been characterized, however, is predicted to result in a gain of function due to other characterized BRAF deletions in the same region (PMID: 26732095)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:4801, pubMedId:26732095, title:Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120., url:http://www.ncbi.nlm.nih.gov/pubmed/26732095]]]], position:485], [id:19429, fullName:BRAF L485_P490delinsF, impact:indel, proteinEffect:gain of function - predicted, geneVariantDescriptions:[[description:BRAF L485_P490delinsF results in a deletion of six amino acids near the alphaC-helix region of the Braf protein kinase domain combined with the insertion of one new amino acid in the same location (PMID: 26732095). L485_P490delinsF is associated with increased Erk phosphorylation in human tumor samples (PMID: 29544532), and increased activation of MEK/ERK signaling in combination with L485_P490delinsY in cultured cells (PMID: 26732095), and therefore is predicted to confer a gain of function to the Braf protein., references:[[id:4801, pubMedId:26732095, title:Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120., url:http://www.ncbi.nlm.nih.gov/pubmed/26732095], [id:12166, pubMedId:29544532, title:BRAF activating mutations involving the β3-αC loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma., url:http://www.ncbi.nlm.nih.gov/pubmed/29544532]]]], position:485], [id:27735, fullName:BRAF V681I, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF V681I lies within the protein kinase domain of the Braf protein (UniProt.org). V681I has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:681], [id:29491, fullName:BRAF T599K, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF T599K lies within the protein kinase domain of the Braf protein (UniProt.org). T599K has been identified in sequencing studies (PMID: 30603682), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Feb 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:14319, pubMedId:30603682, title:Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients., url:http://www.ncbi.nlm.nih.gov/pubmed/30603682]]]], position:599], [id:1794, fullName:BRAF T241P, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF T241P does not lie within any known functional domains of the Braf protein (UniProt.org). T241P results in weak activation of MEK and ERK and does not induce transformation in cell culture (PMID: 19206169), but in one of two cell lines, demonstrates increased cell proliferation and cell viability compared to wild-type Braf (PMID: 29533785), and therefore, its effect on Braf protein function is unknown., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:760, pubMedId:19206169, title:Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum., url:http://www.ncbi.nlm.nih.gov/pubmed/19206169], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:241], [id:29498, fullName:BRAF T599_V600insS, impact:insertion, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF T599_V600insS results in the insertion of a serine (S) in the protein kinase domain of the Braf protein between amino acids 599 and 600 (UniProt.org). T599_V600insS has not been characterized in the scientific literature and therefore, its effect on Braf protein function is unknown (PubMed, Feb 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:599], [id:28196, fullName:BRAF H585Y, impact:missense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF H585Y lies within the protein kinase domain of the Braf protein (UniProt.org). H585Y has not been biochemically characterized, but demonstrates decreased transformation ability in cell culture (PMID: 29533785), and is therefore predicted to confer a loss of function to the Braf protein., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:585], [id:23136, fullName:BRAF T529M, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF T529M lies within the protein kinase domain of the Braf protein (UniProt.org). T529M has been demonstrated to result in resistance to Raf inhibitors in the context of BRAF V600E (PMID: 20538618), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:5859, pubMedId:20538618, title:Gatekeeper mutations mediate resistance to BRAF-targeted therapies., url:http://www.ncbi.nlm.nih.gov/pubmed/20538618]]]], position:529], [id:3178, fullName:BRAF V600A, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF V600A (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600A results in phosphorylated Mek protein levels similar to wild-type Braf and therefore, is predicted to have no effect on Braf protein function (PMID: 26744778)., references:[[id:9739, pubMedId:26744778, title:The yin-yang of kinase activation and unfolding explains the peculiarity of Val600 in the activation segment of BRAF., url:http://www.ncbi.nlm.nih.gov/pubmed/26744778], [id:146, pubMedId:15035987, title:Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., url:http://www.ncbi.nlm.nih.gov/pubmed/15035987]]]], position:600], [id:27718, fullName:BRAF P676S, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF P676S lies within the protein kinase domain of the Braf protein (UniProt.org). P676S has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:676], [id:3174, fullName:BRAF T599I, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF T599I (also reported as T598I) lies within the protein kinase domain of the Braf protein (UniProt.org). T599I results in increased Braf kinase activity, increased downstream Erk signaling (PMID: 15035987), and induces cell proliferation and cell viability in culture (PMID: 29533785)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:146, pubMedId:15035987, title:Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., url:http://www.ncbi.nlm.nih.gov/pubmed/15035987]]]], position:599], [id:29578, fullName:BRAF S465D, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF S465D lies within the protein kinase domain of the Braf protein (UniProt.org). S465D results in basal Mek phosphorylation and Mek phosphorylation upon Ras activation to similar levels of wild-type Braf in culture (PMID: 27034005), and therefore, is predicted to have no effect on Braf protein function., references:[[id:14533, pubMedId:27034005, title:Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles., url:http://www.ncbi.nlm.nih.gov/pubmed/27034005], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:465], [id:28209, fullName:BRAF P731S, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF P731S does not lie within any known functional domains of the Braf protein (UniProt.org). P731S results in increased transformation ability compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:731], [id:3939, fullName:BRAF W604G, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF W604G lies within the protein kinase domain of the Braf protein (UniProt.org). W604G has been identified in the scientific literature (PMID: 29769567, PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:7101, pubMedId:15331929, title:B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome., url:http://www.ncbi.nlm.nih.gov/pubmed/15331929], [id:11670, pubMedId:29769567, title:Genomic alterations of ground-glass nodular lung adenocarcinoma., url:http://www.ncbi.nlm.nih.gov/pubmed/29769567]]]], position:604], [id:29451, fullName:BRAF E586X, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF E586X indicates any Braf missense mutation that results in replacement of the glutamic acid (E) at amino acid 586 by a different amino acid., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:586], [id:27705, fullName:BRAF F294L, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF F294L lies within the protein kinase domain of the Braf protein (UniProt.org). F294L has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:294], [id:3177, fullName:BRAF V471F, impact:missense, proteinEffect:loss of function, geneVariantDescriptions:[[description:BRAF V471F lies within the protein kinase domain of the Braf protein (UniProt.org). V471F results in a loss of Braf kinase activity, however, results in dimerization-dependent activation of Erk signaling and is weakly transforming in cultured cells (PMID: 25348715)., references:[[id:1911, pubMedId:25348715, title:Kinase regulation by hydrophobic spine assembly in cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/25348715], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:471], [id:29446, fullName:BRAF G466X, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF G466X indicates any Braf missense mutation that results in replacement of the glycine (G) at amino acid 466 by a different amino acid., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:466], [id:467, fullName:BRAF G469E, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF G469E is a hotspot mutation that lies within the protein kinase domain of the Braf protein (UniProt.org). The functional effect of G469E is conflicting, as it results in low Braf kinase activity (PMID: 28783719) and intermediate Braf kinase activity (PMID: 15035987), demonstrates Ras-dependent activation of Erk signaling in cell culture (PMID: 28783719), and in one of two cell lines, results in increased cell proliferation and cell viability as compared to wild-type Braf (PMID: 29533785), and therefore, its effect on Braf protein function is unknown., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:9692, pubMedId:28783719, title:Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., url:http://www.ncbi.nlm.nih.gov/pubmed/28783719], [id:146, pubMedId:15035987, title:Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., url:http://www.ncbi.nlm.nih.gov/pubmed/15035987]]]], position:469], [id:29454, fullName:BRAF G596X, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF G596X indicates any Braf missense mutation that results in replacement of the glycine (G) at amino acid 596 by a different amino acid., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:596], [id:1601, fullName:BRAF G469R, impact:missense, proteinEffect:gain of function - predicted, geneVariantDescriptions:[[description:BRAF G469R is a hotspot mutation within the protein kinase domain of the Braf protein (UniProt.org). G469R demonstrates intermediate BRAF kinase activity (PMID: 28783719) and results in constitutive ERK activation in cell culture (PMID: 24920063), and in one of two cell lines leads to increased cell proliferation and cell viability compared to wild-type Braf (PMID: 29533785), and is therefore predicted to confer a gain of function to the Braf protein., references:[[id:4372, pubMedId:24920063, title:Acquired initiating mutations in early hematopoietic cells of CLL patients., url:http://www.ncbi.nlm.nih.gov/pubmed/24920063], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:9692, pubMedId:28783719, title:Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., url:http://www.ncbi.nlm.nih.gov/pubmed/28783719]]]], position:469], [id:4986, fullName:BRAF G596fs, impact:frameshift, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF G596fs results in a change in the amino acid sequence of the Braf protein beginning at aa 596 of 766, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the disruption of the protein kinase domain (UniProt.org), G596fs is predicted to lead to a loss of Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:596], [id:3144, fullName:BRAF I592V, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF I592V lies within the protein kinase domain of the Braf protein (UniProt.org). I592V has been identified in sequencing studies (PMID:  24710085, PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:7101, pubMedId:15331929, title:B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome., url:http://www.ncbi.nlm.nih.gov/pubmed/15331929], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:14439, pubMedId:24710085, title:BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma., url:http://www.ncbi.nlm.nih.gov/pubmed/24710085]]]], position:592], [id:27716, fullName:BRAF P348T, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF P348T lies within the protein kinase domain of the Braf protein (UniProt.org). P348T has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:348], [id:5047, fullName:BRAF V600G, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF V600G (previously reported as V599G) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600G confers a gain of function to Braf as indicated by increased phosphorylation of MEK and ERK and activation of ELK in culture (PMID: 20735442, PMID: 26744778), and in one of two cell lines, increased cell proliferation and viability compared to wild-type Braf (PMID: 29533785)., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:146, pubMedId:15035987, title:Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., url:http://www.ncbi.nlm.nih.gov/pubmed/15035987], [id:12159, pubMedId:20735442, title:Germline mutation in BRAF codon 600 is compatible with human development: de novo p.V600G mutation identified in a patient with CFC syndrome., url:http://www.ncbi.nlm.nih.gov/pubmed/20735442], [id:9739, pubMedId:26744778, title:The yin-yang of kinase activation and unfolding explains the peculiarity of Val600 in the activation segment of BRAF., url:http://www.ncbi.nlm.nih.gov/pubmed/26744778]]]], position:600], [id:1116, fullName:BRAF G478C, impact:missense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF G478C lies within the protein kinase domain of the Braf protein (UniProt.org). G478C demonstrates a lack of Braf kinase activity in cell culture (PMID: 22926515), and therefore is predicted to confer a loss of function to the Braf protein., references:[[id:463, pubMedId:22926515, title:ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers., url:http://www.ncbi.nlm.nih.gov/pubmed/22926515], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:478], [id:465, fullName:BRAF G464V, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF G464V (also reported as G463V) lies within the protein kinase domain of the Braf protein (UniProt.org). G464V results in increased Braf kinase activity and increased downstream Mek and Erk activation (PMID: 12068308, PMID: 26343582), and in one of two cell lines, increased cell proliferation and viability compared to wild-type Braf in culture (PMID: 29533785)., references:[[id:7141, pubMedId:26343582, title:BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition., url:http://www.ncbi.nlm.nih.gov/pubmed/26343582], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:637, pubMedId:12068308, title:Mutations of the BRAF gene in human cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/12068308], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:464], [id:28191, fullName:BRAF G596S, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF G596S lies within the protein kinase domain of the Braf protein (UniProt.org). G596S has not been biochemically characterized, but results in increased transformation ability compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:596], [id:29473, fullName:BRAF P731T, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF P731T does not lie within any known functional domains of the Braf protein (UniProt.org). P731T has been identified in the scientific literature (PMID: 29320312), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Feb 2019)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:13171, pubMedId:29320312, title:Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study., url:http://www.ncbi.nlm.nih.gov/pubmed/29320312], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed]]]], position:731], [id:25271, fullName:BRAF L485Y, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF L485Y lies within the protein kinase domain of the Braf protein (UniProt.org). L485Y has been demonstrated to confer resistance to Raf inhibitor in cell culture (PMID: 19276360), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:6516, pubMedId:19276360, title:Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression., url:http://www.ncbi.nlm.nih.gov/pubmed/19276360], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:485], [id:5039, fullName:BRAF T599_V600insEAT, impact:insertion, proteinEffect:gain of function - predicted, geneVariantDescriptions:[[description:BRAF T599_V600insEAT results in the insertion of 3 amino acids in the protein kinase domain of the Braf protein between amino acids 599 and 600 (UniProt.org). T599_V600insEAT has not been characterized, however other insertions between T599 and V600 are activating thus, T599_V600insEAT is predicted to lead to a gain of Braf protein function (PMID: 16501605, PMID: 17297294, PMID: 21190184)., references:[[id:1910, pubMedId:21190184, title:Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma., url:http://www.ncbi.nlm.nih.gov/pubmed/21190184], [id:2112, pubMedId:17297294, title:Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/17297294], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:1892, pubMedId:16501605, title:Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma., url:http://www.ncbi.nlm.nih.gov/pubmed/16501605]]]], position:599], [id:29440, fullName:BRAF T241X, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF T241X indicates any Braf missense mutation that results in replacement of the threonine (T) at amino acid 241 by a different amino acid., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:241], [id:5029, fullName:BRAF D594_T599dup, impact:duplication, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF D594_T599dup (also referred to as T599_V600insDFGLAT) results in the insertion of six amino acids in the protein kinase domain of the Braf protein between amino acids 599 and 600 (UniProt.org).BRAF D594_T599dup results in increased colony formation and downstream Mek and Erk activation in cultured cells (PMID: 17297294)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:2112, pubMedId:17297294, title:Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/17297294]]]], position:594], [id:1161, fullName:BRAF V600X, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF V600X indicates any Braf missense mutation that results in replacement of the the valine (V) at amino acid 600 by a different amino acid. BRAF V600 mutations are hotspot mutations that often result in increased Braf kinase activity (PMID: 15035987)., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10], [id:146, pubMedId:15035987, title:Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., url:http://www.ncbi.nlm.nih.gov/pubmed/15035987]]]], position:600], [id:2560, fullName:BRAF F595L, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF F595L lies within the protein kinase domain of the Braf protein (UniProt.org). F595L results in intermediate Braf kinase activity and is transforming in cell culture (PMID: 15035987, PMID: 26582644, PMID: 29533785), and works cooperatively with oncogenic Ras to activate MEK/ERK signaling (PMID: 26582644), however, demonstrates low Braf kinase activity in vitro (PMID: 28783719), and therefore, its effect on Braf protein function is unknown., references:[[id:146, pubMedId:15035987, title:Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., url:http://www.ncbi.nlm.nih.gov/pubmed/15035987], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:9692, pubMedId:28783719, title:Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., url:http://www.ncbi.nlm.nih.gov/pubmed/28783719], [id:9695, pubMedId:26582644, title:Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling., url:http://www.ncbi.nlm.nih.gov/pubmed/26582644]]]], position:595], [id:4987, fullName:BRAF G606A, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF G606A lies within the protein kinase domain of the Braf protein (UniProt.org). G606A has been identified in sequencing studies (PMID: 21825258), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:7103, pubMedId:21825258, title:Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations., url:http://www.ncbi.nlm.nih.gov/pubmed/21825258], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:606], [id:2591, fullName:BRAF K601N, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF K601N lies within the protein kinase domain of the Braf protein (UniProt.org). K601N confers a gain of function on Braf, as indicated by increased phosphorylation of MEK and ERK in cell in culture (PMID: 24434212) and induction of cell proliferation and cell viability in culture (PMID: 29533785)., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:1131, pubMedId:24434212, title:Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy., url:http://www.ncbi.nlm.nih.gov/pubmed/24434212]]]], position:601], [id:27706, fullName:BRAF G104E, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF G104E lies within the protein kinase domain of the Braf protein (UniProt.org). G104E has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:104], [id:13401, fullName:BRAF E611D, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF E611D lies within the protein kinase domain of the Braf protein (UniProt.org). E611D has been identified in sequencing studies (PMID: 15935100), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:7100, pubMedId:15935100, title:Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases., url:http://www.ncbi.nlm.nih.gov/pubmed/15935100], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:611], [id:2524, fullName:BRAF E586K, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF E586K (also reported as E585K) lies within the protein kinase domain of the Braf protein (UniProt.org). E586K results in increased Braf kinase activity, and activation of Mek and Erk in cell culture (PMID: 15035987, PMID: 22510884), and increases cell proliferation and viability compared to wild-type Braf in one of two cell lines (PMID: 29533785)., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:5712, pubMedId:22510884, title:Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling., url:http://www.ncbi.nlm.nih.gov/pubmed/22510884], [id:146, pubMedId:15035987, title:Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., url:http://www.ncbi.nlm.nih.gov/pubmed/15035987]]]], position:586], [id:28190, fullName:BRAF G563D, impact:missense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF G563D lies within the protein kinase domain of the Braf protein (UniProt.org). G563D has not been biochemically characterized, but demonstrates decreased transformation ability in cell culture compared to wild-type Braf (PMID: 29533785), and therefore is predicted to confer a loss of function to the Braf protein., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:563], [id:2641, fullName:BRAF G466R, impact:missense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF G466R (previously reported as G465R) lies within the glycine-rich loop in the protein kinase domain of the Braf protein (PMID: 14681681). G466R results in impaired Braf kinase activity, but activates Erk signaling in cell culture (PMID: 15046639), and in one of two cell lines, G466R decreased cell proliferation and cell viability compared to wild-type Braf (PMID: 29533785), and is therefore predicted to confer a loss of function to the Braf protein., references:[[id:1166, pubMedId:15046639, title:Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis., url:http://www.ncbi.nlm.nih.gov/pubmed/15046639], [id:1167, pubMedId:14681681, title:Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9., url:http://www.ncbi.nlm.nih.gov/pubmed/14681681], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:466], [id:3185, fullName:BRAF W604del, impact:deletion, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF W604del results in the deletion of one amino acid in the protein kinase domain of the Braf protein at amino acid 604 (UniProt.org). W604del has been identified in sequencing studies (PMID: 15513360), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:7113, pubMedId:15513360, title:Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas., url:http://www.ncbi.nlm.nih.gov/pubmed/15513360], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:604], [id:28201, fullName:BRAF L613F, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF L613F lies within the protein kinase domain of the Braf protein (UniProt.org). L613F results in increased transformation ability as compared to wild-type Braf, in one of two cell lines in culture (PMID: 29533785), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:613], [id:19432, fullName:BRAF T488_Q493delinsK, impact:indel, proteinEffect:gain of function - predicted, geneVariantDescriptions:[[description:BRAF T488_Q493delinsK results in the deletion of six amino acids near the alphaC-helix region of the Braf protein kinase domain combined with the insertion of one new amino acid in the same location (PMID: 26732095). T488_Q493delinsK has not been characterized, however, is predicted to result in a gain of function due to other characterized BRAF deletions in the same region (PMID: 26732095)., references:[[id:4801, pubMedId:26732095, title:Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120., url:http://www.ncbi.nlm.nih.gov/pubmed/26732095]]]], position:488], [id:3142, fullName:BRAF I582M, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF I582M lies within the protein kinase domain of the Braf protein (UniProt.org). I582M has been identified in sequencing studies (PMID: 30268455, PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:7101, pubMedId:15331929, title:B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome., url:http://www.ncbi.nlm.nih.gov/pubmed/15331929], [id:14442, pubMedId:30268455, title:Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA., url:http://www.ncbi.nlm.nih.gov/pubmed/30268455]]]], position:582], [id:28212, fullName:BRAF Y656D, impact:missense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF Y656D lies within the protein kinase domain of the Braf protein (UniProt.org). Y656D has not been biochemically characterized, but demonstrates decreased transformation ability in cell culture (PMID: 29533785), and is therefore predicted to confer a loss of function to the Braf protein., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:656], [id:456, fullName:BRAF K601E, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF K601E lies within the activation segment in the kinase domain of the Braf protein (PMID: 15343278). K601E results in increased Braf kinase activity and downstream activation of MEK and ERK in cell culture (PMID: 22798288, PMID: 28783719) and induces cell proliferation and cell viability in culture (PMID: 29533785)., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:9692, pubMedId:28783719, title:Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., url:http://www.ncbi.nlm.nih.gov/pubmed/28783719], [id:3, pubMedId:22798288, title:BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors., url:http://www.ncbi.nlm.nih.gov/pubmed/22798288], [id:9694, pubMedId:15343278, title:Switching on kinases: oncogenic activation of BRAF and the PDGFR family., url:http://www.ncbi.nlm.nih.gov/pubmed/15343278]]]], position:601], [id:3515, fullName:BRAF G466A, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF G466A (also reported as G465A) lies within the protein kinase domain of the Braf protein (UniProt.org). The functional effect of G466A (also reported as G465A) on Braf is unclear as it has been characterized both as having intermediate Braf kinase activity (PMID: 15035987) and low Braf kinase activity (PMID: 28783719), leads to Ras-dependent activation of downstream Erk in cell culture (PMID: 28783719), and in one of two cell lines increased cell proliferation and cell viability compared to wild-type Braf (PMID: 29533785)., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:9692, pubMedId:28783719, title:Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., url:http://www.ncbi.nlm.nih.gov/pubmed/28783719], [id:146, pubMedId:15035987, title:Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., url:http://www.ncbi.nlm.nih.gov/pubmed/15035987], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:466], [id:27724, fullName:BRAF R671Q, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF R671Q lies within the protein kinase domain of the Braf protein (UniProt.org). R671Q has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:671], [id:23103, fullName:BRAF D594Y, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF D594Y lies within the protein kinase domain of the Braf protein (UniProt.org). D594Y has been identified in sequencing studies (PMID: 29106415, PMID: 28486044), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:12148, pubMedId:28486044, title:Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/28486044], [id:10426, pubMedId:29106415, title:Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers., url:http://www.ncbi.nlm.nih.gov/pubmed/29106415]]]], position:594], [id:28589, fullName:BRAF A762E, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF A762E does not lie within any known functional domains of the Braf protein (UniProt.org). A762E has been demonstrated to confer resistance to Egfr inhibitors in culture (PMID: 27478040), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:8124, pubMedId:27478040, title:High-throughput Phenotyping of Lung Cancer Somatic Mutations., url:http://www.ncbi.nlm.nih.gov/pubmed/27478040], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:762], [id:27712, fullName:BRAF N49I, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF N49I lies within the protein kinase domain of the Braf protein (UniProt.org). N49I has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:49], [id:27726, fullName:BRAF S364L, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF S364L lies within the protein kinase domain of the Braf protein (UniProt.org). S364L has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:364], [id:29447, fullName:BRAF S467X, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF S467X indicates any Braf missense mutation that results in replacement of the serine (S) at amino acid 467 by a different amino acid., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:467], [id:3150, fullName:BRAF L584F, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF L584F lies within the protein kinase domain of the Braf protein (UniProt.org). L584F results in increased transformation ability compared to wild-type Braf in one of two different cell lines in culture (PMID: 29533785), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:584], [id:3153, fullName:BRAF R444W, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF R444W does not lie within any known functional domains of the Braf protein (UniProt.org). R444W has been identified in sequencing studies (PMID: 15578519), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:7111, pubMedId:15578519, title:BRAF mutations distinguish anorectal from cutaneous melanoma at the molecular level., url:http://www.ncbi.nlm.nih.gov/pubmed/15578519], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:444], [id:3524, fullName:BRAF P403fs, impact:frameshift, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF P403fs results in a change in the amino acid sequence of the Braf protein beginning at aa 403 of 766, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), P403fs is predicted to lead to a loss of Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:403], [id:27733, fullName:BRAF V590I, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF V590I lies within the protein kinase domain of the Braf protein (UniProt.org). V590I has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:590], [id:4991, fullName:BRAF N581T, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF N581T lies within the protein kinase domain of the Braf protein (UniProt.org). N581T has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:581], [id:27730, fullName:BRAF T401I, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF T401I lies within the protein kinase domain of the Braf protein (UniProt.org). T401I has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:401], [id:27709, fullName:BRAF K698R, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF K698R lies within the protein kinase domain of the Braf protein (UniProt.org). K698R has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:698], [id:5019, fullName:BRAF R462K, impact:missense, proteinEffect:no effect - predicted, geneVariantDescriptions:[[description:BRAF R462K lies within the protein kinase domain of the Braf protein (UniProt.org). R462K has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Braf in culture (PMID: 29533785), and therefore is predicted to have no effect on Braf protein function., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:462], [id:898, fullName:BRAF D594V, impact:missense, proteinEffect:loss of function, geneVariantDescriptions:[[description:BRAF D594V lies within the protein kinase domain of the Braf protein (UniProt.org). D594V results in impaired Braf kinase activity, and decreased activation of Erk, Mek, and CRAF in cell culture (PMID: 28947956, PMID: 15035987), and has decreased transforming ability in one of two cell lines compared to wild-type Braf in culture (PMID: 29533785)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:12147, pubMedId:28947956, title:Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib., url:http://www.ncbi.nlm.nih.gov/pubmed/28947956], [id:146, pubMedId:15035987, title:Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., url:http://www.ncbi.nlm.nih.gov/pubmed/15035987]]]], position:594], [id:454, fullName:BRAF V600D, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF V600D (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600D confers a gain of function to the Braf protein as demonstrated by increased kinase activity, downstream signaling, and the ability to transform cells in vitro (PMID: 15035987)., references:[[id:146, pubMedId:15035987, title:Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., url:http://www.ncbi.nlm.nih.gov/pubmed/15035987]]]], position:600], [id:455, fullName:BRAF V600R, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF V600R (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600R confers a gain of function to the Braf protein as demonstrated by increased Braf kinase activity, downstream signaling, and the ability to transform cells in culture (PMID: 15035987, PMID: 29533785)., references:[[id:146, pubMedId:15035987, title:Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., url:http://www.ncbi.nlm.nih.gov/pubmed/15035987], [id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785]]]], position:600], [id:5044, fullName:BRAF T599_V600insETT, impact:insertion, proteinEffect:gain of function - predicted, geneVariantDescriptions:[[description:BRAF T599_V600insETT results in the insertion of 3 amino acids in the protein kinase domain of the Braf protein between amino acids 599 and 600 (UniProt.org). BRAF T599_V600insETT has not been characterized, however other insertions between T599 and V600 are activating thus, T599_V600insETT is predicted to lead to a gain of Braf protein function (PMID: 16501605, PMID: 17297294, PMID: 21190184)., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:1892, pubMedId:16501605, title:Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma., url:http://www.ncbi.nlm.nih.gov/pubmed/16501605], [id:1910, pubMedId:21190184, title:Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma., url:http://www.ncbi.nlm.nih.gov/pubmed/21190184], [id:2112, pubMedId:17297294, title:Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/17297294]]]], position:599], [id:613, fullName:BRAF Y538H, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF Y538H lies within the protein kinase domain of the Braf protein (UniProt.org). Y538H has not been characterized in the scientific literature and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:538], [id:603, fullName:BRAF R347*, impact:nonsense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF R347* results in a premature truncation of the of the 766 aa Braf protein at aa 347 (UniProt.org). Due to the loss of a portion of the protein kinase domain (UniProt.org), R347* is predicted to lead to a loss of Braf protein function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:347], [id:3155, fullName:BRAF R603*, impact:nonsense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF R603* results in a premature truncation within the protein kinase domain of the Braf protein at amino acid 603 of 766 (UniProt.org, PMID: 11032810). Due to the loss of the protein kinase domain (UniProt.org, PMID: 11032810), R603* is predicted to lead to a loss of function., references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:1908, pubMedId:11032810, title:Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601., url:http://www.ncbi.nlm.nih.gov/pubmed/11032810]]]], position:603], [id:49, fullName:BRAF V600E, impact:missense, proteinEffect:gain of function, geneVariantDescriptions:[[description:BRAF V600E (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600E confers a gain of function to the Braf protein as demonstrated by increased Braf kinase activity, downstream signaling, and the ability to transform cells in culture (PMID: 15035987, PMID: 29533785)., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:146, pubMedId:15035987, title:Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF., url:http://www.ncbi.nlm.nih.gov/pubmed/15035987]]]], position:600], [id:29452, fullName:BRAF D594X, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF D594X indicates any Braf missense mutation that results in replacement of the aspartic acid (D) at amino acid 594 by a different amino acid., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:594], [id:29455, fullName:BRAF L597X, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF L597X indicates any Braf missense mutation that results in replacement of the leucine (L) at amino acid 597 by a different amino acid., references:[[id:275, pubMedId:10, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed/10]]]], position:597], [id:28187, fullName:BRAF E648Q, impact:missense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF E648Q lies within the protein kinase domain of the Braf protein (UniProt.org). E648Q has not been biochemically characterized, but demonstrates decreased transformation ability in cell culture compared to wild-type Braf (PMID: 29533785), and is therefore predicted to confer a loss of function to the Braf protein., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:648], [id:23137, fullName:BRAF T529N, impact:missense, proteinEffect:unknown, geneVariantDescriptions:[[description:BRAF T529N lies within the protein kinase domain of the Braf protein (UniProt.org). T529N has been demonstrated to result in resistance to Raf inhibitors in the context of BRAF V600E (PMID: 20538618, PMID: 20807807), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2019)., references:[[id:14535, pubMedId:20807807, title:A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF., url:http://www.ncbi.nlm.nih.gov/pubmed/20807807], [id:285, pubMedId:null, title:null, url:http://www.ncbi.nlm.nih.gov/pubmed], [id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:5859, pubMedId:20538618, title:Gatekeeper mutations mediate resistance to BRAF-targeted therapies., url:http://www.ncbi.nlm.nih.gov/pubmed/20538618]]]], position:529], [id:25029, fullName:BRAF A598_T599insARC, impact:insertion, proteinEffect:gain of function - predicted, geneVariantDescriptions:[[description:BRAF A598_T599insARC results in the insertion of 3 amino acids in the protein kinase domain of the Braf protein between amino acids 598 and 599 (UniProt.org). BRAF A598_T599insARC has not been characterized, however other insertions between A598 and T599 are activating thus, A598_T599insARC is predicted to lead to a gain of Braf protein function (PMID: 16501605). 

, references:[[id:295, pubMedId:null, title:null, url:www.uniprot.org], [id:1892, pubMedId:16501605, title:Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma., url:http://www.ncbi.nlm.nih.gov/pubmed/16501605]]]], position:598], [id:28203, fullName:BRAF L678I, impact:missense, proteinEffect:loss of function - predicted, geneVariantDescriptions:[[description:BRAF L678I lies within the protein kinase domain of the Braf protein (UniProt.org). L678I has not been biochemically characterized, but demonstrates decreased transformation ability in cell culture (PMID: 29533785), and is therefore predicted to confer a loss of function to the Braf protein., references:[[id:11238, pubMedId:29533785, title:Systematic Functional Annotation of Somatic Mutations in Cancer., url:http://www.ncbi.nlm.nih.gov/pubmed/29533785], [id:295, pubMedId:null, title:null, url:www.uniprot.org]]]], position:678]]